{"gene":"FOXC2","run_date":"2026-04-28T17:46:04","timeline":{"discoveries":[{"year":1997,"finding":"FOXC2 (MFH-1) protein acts as a positive transcriptional transactivator, as demonstrated by transcriptional activity assays of the mouse and human MFH-1 proteins, and is essential for aortic arch patterning and skeletogenesis in vivo as shown by targeted gene knockout in mice.","method":"Transcriptional activity assay; targeted gene knockout in mice with phenotypic analysis","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro transactivation assay plus knockout model with defined phenotypic readout, replicated across two papers (PMID:9409679, PMID:9169153)","pmids":["9409679","9169153"],"is_preprint":false},{"year":2000,"finding":"Loss-of-function mutations (nonsense and frameshift) in FOXC2, a forkhead/winged-helix transcription factor, cause lymphedema-distichiasis syndrome via FOXC2 haploinsufficiency, establishing FOXC2 as required for lymphatic development.","method":"Mutation identification by sequencing; genetic linkage; FISH mapping","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (sequencing, linkage, FISH), replicated extensively across subsequent studies","pmids":["11078474"],"is_preprint":false},{"year":2001,"finding":"FOXC2 overexpression in adipocytes increases sensitivity of the beta-adrenergic-cAMP-PKA signaling pathway by altering adipocyte PKA holoenzyme composition, leading to a lean, insulin-sensitive phenotype and counteracting obesity and hypertriglyceridemia.","method":"Transgenic mouse overexpression; gene expression profiling; PKA holoenzyme composition analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 — mechanistic pathway placement with in vivo gain-of-function and biochemical PKA assay, single high-impact study with multiple orthogonal methods","pmids":["11551504"],"is_preprint":false},{"year":2001,"finding":"Foxc1 and Foxc2 have dose-dependent, cooperative roles in cardiovascular development and somitogenesis; compound Foxc1;Foxc2 homozygous knockout mice show complete absence of segmented paraxial mesoderm and profound defects in branchial arches and blood vessel remodeling, with loss of Notch pathway target gene expression (Mesp1, Mesp2, Hes5, Notch1, Dll1, Lfng, ephrinB2), placing Foxc1/2 upstream of the Notch/Delta/Mesp regulatory loop.","method":"Compound knockout mouse genetics; gene expression analysis; epistasis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with compound knockouts and multiple molecular readouts, replicated in subsequent cardiovascular studies","pmids":["11562355"],"is_preprint":false},{"year":2001,"finding":"Truncating mutations throughout FOXC2 that disrupt the DNA-binding domain and/or C-terminal alpha-helices essential for transcription activation cause multiple lymphedema syndromes, demonstrating these domains are functionally required.","method":"Mutation sequencing in 86 lymphedema families; domain-function correlation","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — large patient cohort with domain mapping, but functional assay not directly performed in this study","pmids":["11371511"],"is_preprint":false},{"year":2004,"finding":"FoxC2 inhibits white adipocyte differentiation (adipogenesis) by blocking the ability of PPARgamma to promote expression of a subset of adipogenic genes (C/EBPalpha, adiponectin, perilipin) without affecting PPARgamma DNA binding or transactivation from a PPARgamma response element directly.","method":"Overexpression in 3T3-L1 preadipocytes and Swiss fibroblasts; PPARgamma overexpression rescue experiments; reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal cell-based assays with defined molecular pathway placement and PPARgamma rescue experiments","pmids":["15277530"],"is_preprint":false},{"year":2006,"finding":"Foxc1 and Foxc2 directly activate the Dll4 promoter via a Foxc-binding site to induce arterial cell specification upstream of Notch signaling; compound Foxc1;Foxc2 mutant embryos lack arterial markers and display arteriovenous malformations and defects in lymphatic sprouting due to reduced VEGF-C.","method":"Compound knockout mouse genetics; in vitro overexpression; direct promoter activation assay (Dll4 promoter with Foxc-binding site); gene expression analysis","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 1-2 — direct promoter binding and activation combined with in vivo knockout epistasis, replicated across multiple vascular studies","pmids":["16678147"],"is_preprint":false},{"year":2006,"finding":"Foxc1 and Foxc2 are required for cardiac outflow tract morphogenesis; compound mutants show downregulation of Tbx1 and Fgf8/10 in the second heart field and extensive neural crest cell apoptosis during migration, placing Foxc genes upstream of the Tbx1-FGF cascade.","method":"Compound knockout mouse genetics; gene expression analysis; cell proliferation and apoptosis assays","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with defined molecular cascade identification","pmids":["16839542"],"is_preprint":false},{"year":2007,"finding":"FOXC2 expression is induced by EMT-inducing signals (TGF-beta1, Snail, Twist, Goosecoid) and is required for the mesenchymal component of EMT; knockdown impairs lung metastasis of mammary carcinoma cells, and overexpression enhances metastatic ability in mouse models.","method":"Loss-of-function (RNAi) and gain-of-function (overexpression) in mouse mammary carcinoma cells; in vivo lung metastasis assay; gene expression profiling","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — reciprocal gain/loss-of-function with in vivo readout, multiple EMT inducers tested, highly cited foundational study","pmids":["17537911"],"is_preprint":false},{"year":2008,"finding":"Foxc2 directly regulates angiogenesis by binding to multiple Forkhead-binding elements within the Itgb3 (integrin beta3) promoter to drive Itgb3 expression; Foxc2 overexpression enhances endothelial cell migration and adhesion, an effect blocked by Itgb3 neutralizing antibody; Foxc2 heterozygous mutant mice show reduced Itgb3 expression and impaired microvessel outgrowth.","method":"Gene expression profiling; promoter binding assay; Itgb3 neutralizing antibody rescue; aortic ring ex vivo sprouting assay; Foxc2 heterozygous mouse model","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — direct promoter binding demonstrated, functional rescue with neutralizing antibody, corroborated with in vivo mouse model","pmids":["18579532"],"is_preprint":false},{"year":2009,"finding":"FOXC2 subcellular localization determines its function: cytoplasmic FOXC2 in normal epithelial cells promotes epithelial redifferentiation, while nuclear FOXC2 promotes mesenchymal/EMT phenotype; silencing FOXC2 in epithelial cells causes EMT and increased migration, whereas in fibroblasts it causes increased epithelial marker expression; overexpression in renal epithelial cells drives de novo nuclear localization and mesenchymal phenotype.","method":"RNAi knockdown; overexpression; subcellular fractionation/immunofluorescence; kidney ischemia-reperfusion in vivo model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2-3 — localization-function linkage established by RNAi and overexpression with defined phenotypic readouts, single lab","pmids":["19935708"],"is_preprint":false},{"year":2009,"finding":"Pax3 and Foxc2 exhibit reciprocal transcriptional repression in the somite dermomyotome, and the Pax3:Foxc2 ratio determines myogenic versus vascular smooth muscle cell fate in multipotent progenitors.","method":"Genetic approaches (compound mouse mutants); somite explant manipulation; epistasis analysis","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with multiple approaches and defined cell fate readouts","pmids":["20059958"],"is_preprint":false},{"year":2009,"finding":"Foxc2 stimulates osteoblast differentiation by activating canonical Wnt-beta-catenin/TCF-LEF signaling, and this effect is partially mediated by protein kinase A (PKA), as the PKA inhibitor H-89 suppresses Foxc2-mediated TCF/LEF transcriptional activity.","method":"Electroporation overexpression in cranial suture mesenchymal cells; siRNA knockdown; reporter (TCF/LEF luciferase) assay; pharmacological inhibition (H-89)","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple methods but single lab, pathway placement via reporter assay and inhibitor","pmids":["19540201"],"is_preprint":false},{"year":2010,"finding":"Foxc2 directly binds to the p120-catenin promoter between positions +267 and +282 (confirmed by EMSA) and transcriptionally represses p120-catenin expression in NSCLC cells; FOXC2 silencing restores p120-catenin and subsequently E-cadherin levels.","method":"Serial deletion promoter analysis; EMSA (electromobility shift assay); RNAi silencing; reporter assay","journal":"Molecular cancer research : MCR","confidence":"High","confidence_rationale":"Tier 1-2 — direct DNA binding confirmed by EMSA plus functional RNAi rescue, single lab but multiple orthogonal methods","pmids":["20460685"],"is_preprint":false},{"year":2011,"finding":"FOXC2 expression in adipocytes induces mitochondriogenesis, elongated mitochondrial morphology, increased aerobic metabolic capacity, and specifically trans-activates the nuclear-encoded mitochondrial transcription factor A (mtTFA/Tfam) gene promoter—a function unique among tested forkhead genes.","method":"Quantitative RT-PCR; promoter assay (trans-activation); electron microscopy; oxygen consumption and palmitate oxidation measurements","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 1-2 — direct promoter trans-activation combined with multiple functional metabolic readouts","pmids":["21270254"],"is_preprint":false},{"year":2011,"finding":"Foxc2 promotes osteoblastogenesis by directly binding to a Forkhead-binding element in the integrin beta1 promoter and up-regulating integrin beta1 expression, with downstream activation of Akt and ERK phosphorylation.","method":"Promoter binding assay (direct binding to Forkhead element); siRNA knockdown; overexpression in MC3T3-E1 and primary calvarial cells; ex vivo organ culture","journal":"Bone","confidence":"Medium","confidence_rationale":"Tier 2 — direct promoter binding demonstrated, functional cell assays, single lab","pmids":["21640215"],"is_preprint":false},{"year":2012,"finding":"PROX1, FOXC2, and flow (shear stress) coordinately control expression of connexin37 (gap junction protein) and activation of calcineurin/NFAT signaling to mediate lymphatic valve formation; FOXC2 mediates mechanosensory responses to shear stress in lymphatic endothelial cells.","method":"In vitro shear stress experiments; genetic mouse models; gene expression analysis; functional valve morphogenesis assays","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 — in vitro mechanotransduction assay combined with in vivo genetic models and multiple molecular readouts","pmids":["22306086"],"is_preprint":false},{"year":2012,"finding":"SUMOylation of FOXC2 occurs primarily at one consensus synergy control motif (with minor contribution of a second site) and negatively regulates FOXC2 transcriptional activity; SUMOylation can be reconstituted in vitro with purified components and reversed by SUMO protease SENP2; SUMOylation-deficient FOXC2 mutants show higher transcriptional activity.","method":"In vitro SUMOylation reconstitution with purified components; SENP2 protease reversal; mutagenesis of synergy control motifs; transcriptional activity assay; detection of endogenous SUMO2/3-modified FOXC1","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro with purified components plus mutagenesis and functional assays","pmids":["22493429"],"is_preprint":false},{"year":2013,"finding":"FOXC2 is phosphorylated on eight evolutionarily conserved proline-directed serine/threonine residues; phosphorylation regulates FOXC2 chromatin recruitment in a site-selective (rheostat-like) manner in lymphatic endothelial cells; phosphorylation-deficient FOXC2 mutant fails to induce vascular remodeling in vivo.","method":"Genome-wide ChIP-seq in lymphatic endothelial cells; phosphorylation-deficient mutagenesis; in vivo vascular remodeling assay; mass spectrometry","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 — genome-wide location analysis combined with mutagenesis and in vivo functional validation","pmids":["23878394"],"is_preprint":false},{"year":2013,"finding":"SENP3 de-SUMOylates FOXC2, potentiating its transcriptional activity; de-SUMOylated FOXC2 transcriptionally activates N-cadherin expression, promoting EMT in gastric cancer; reactive oxygen species-induced de-SUMOylation of FOXC2 is blocked by silencing SENP3.","method":"Biochemical SUMO assay; SENP3 overexpression/knockdown; target gene expression analysis; nude mouse model","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical identification of FOXC2 as SENP3 substrate with functional consequence on transcription and EMT, multiple approaches","pmids":["25216525"],"is_preprint":false},{"year":2013,"finding":"Egr-1 in adipocytes suppresses FOXC2 expression, thereby promoting energy storage in white adipose tissue; Egr-1 null mice show elevated FOXC2 expression and its target genes, leading to increased energy expenditure and protection from diet-induced obesity.","method":"Egr-1 null mouse model; gene expression analysis in WAT; correlation of Egr-1 and FOXC2 expression","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2-3 — knockout mouse with defined FOXC2 pathway placement, but direct Egr-1 binding to FOXC2 promoter not demonstrated in this study","pmids":["23502673"],"is_preprint":false},{"year":2013,"finding":"BSTA promotes mTORC2-mediated phosphorylation of Akt1 at Ser473, which suppresses FOXC2 expression to stimulate adipocyte differentiation; the mTORC2-BSTA-Akt1-FoxC2 signaling axis is required for adipogenesis.","method":"BSTA gene-trap murine ES cells; co-immunoprecipitation (BSTA-Akt1 complex); phosphorylation assays; FOXC2 expression analysis","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 2 — Co-IP demonstrating complex, genetic loss-of-function, and defined signaling cascade with pathway placement","pmids":["23300339"],"is_preprint":false},{"year":2014,"finding":"Casein kinase 2 (CK2) associates with Foxc2 and phosphorylates it at serine 124 in vitro; CK2-mediated phosphorylation at S124 maintains Foxc2 in the cytoplasm of normal epithelial cells; mutation of S124 to leucine causes constitutive nuclear Foxc2 localization and mesenchymal gene expression, while S124D phosphomimetic causes constitutive cytoplasmic localization; loss of CK2beta in breast cancer correlates with nuclear FOXC2.","method":"In vitro kinase assay (CK2 phosphorylation of Foxc2); mutagenesis (S124L, S124D); subcellular localization imaging; CK2 knockdown/overexpression; cell migration assays","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay plus mutagenesis of phosphosite with functional localization and phenotypic readouts","pmids":["25486430"],"is_preprint":false},{"year":2014,"finding":"FOXC2 acts as a transcriptional repressor of p120-catenin (CTNND1) downstream of PKCalpha, leading to destabilization of E-cadherin at adherens junctions; ChIP confirmed direct FOXC2 binding to the p120-catenin promoter; inhibition of PKCalpha or FOXC2 rescues p120-catenin and E-cadherin, reducing tumor cell migration.","method":"Chromatin immunoprecipitation (ChIP); luciferase promoter reporter assay; Western blot; transwell migration/invasion assays; RNAi","journal":"BMC cancer","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP confirmed direct DNA binding, promoter reporter assay, functional cell migration rescue","pmids":["29216867"],"is_preprint":false},{"year":2015,"finding":"Cyclin-dependent kinase 5 (Cdk5) phosphorylates Foxc2 in lymphatic endothelial cells; Cdk5 is an essential regulator of lymphatic vessel development and valve formation, mechanistically linked through Foxc2 as its key substrate.","method":"Endothelial-specific Cdk5 knockdown; identification of Foxc2 as Cdk5 substrate; lymphatic vessel and valve phenotype analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — substrate identification with in vivo endothelial-specific knockdown and mechanistic pathway linkage","pmids":["26027726"],"is_preprint":false},{"year":2015,"finding":"p38 kinase phosphorylates FOXC2 at serine 367 (S367) to regulate its protein stability and function; the phosphomimetic FOXC2(S367E) mutant is refractory to p38 inhibition while FOXC2(S367A) non-phosphorylatable mutant fails to elicit EMT or upregulate ZEB1; p38-FOXC2 signaling selectively promotes metastasis without affecting primary tumor growth; ZEB1 is a downstream transcriptional target of FOXC2.","method":"Site-directed mutagenesis (S367E, S367A); orthotopic syngeneic mouse tumor model; p38 inhibitor (SB203580) treatment; gene expression analysis; in vitro EMT assays","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 — phosphosite mutagenesis with in vivo and in vitro validation, multiple orthogonal methods","pmids":["27292262"],"is_preprint":false},{"year":2015,"finding":"Notch signaling acts upstream of Foxc2 in hemogenic endothelial cells to promote definitive hematopoiesis; Foxc2 is required for proper development of definitive hematopoiesis downstream of Notch, as shown in zebrafish, mouse embryos, and mouse ES cell differentiation assays.","method":"Mouse ES cell differentiation; zebrafish loss-of-function; mouse embryo Foxc2 analysis; epistasis with Notch induction","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in multiple model systems establishing pathway position","pmids":["25587036"],"is_preprint":false},{"year":2016,"finding":"FOXC1 and FOXC2 regulate ERK signaling in lymphatic endothelial cells; LEC-specific deletion of Foxc1 or Foxc2 causes increased LEC proliferation and enlarged, abnormal lymphatic vessels associated with ERK hyperactivation; pharmacological ERK inhibition rescues the enlarged lymphatic vessel phenotype in FOXC-deficient embryos.","method":"LEC-specific conditional knockout mice; ERK signaling analysis; pharmacological ERK inhibition in utero; gene expression of Ras regulators","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — conditional knockout with defined pathway identification and pharmacological rescue, replicated with multiple genetic combinations","pmids":["27214551"],"is_preprint":false},{"year":2016,"finding":"p38MAPK signaling is a druggable upstream regulator of FOXC2, and FOXC2 elevated by p38 promotes an AR-negative stem-like prostate cancer phenotype resistant to androgen deprivation therapy; p38 inhibition restores epithelial attributes and reduces circulating tumor cells in vivo.","method":"p38 inhibitor (SB203580) treatment; FOXC2 expression analysis; in vivo tumor model with circulating tumor cell analysis; RNAi","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2-3 — defined signaling axis with in vivo validation, but phosphosite not mapped in this study","pmids":["26804168"],"is_preprint":false},{"year":2016,"finding":"FOXC2 disease mutations outside the forkhead domain cause either loss or gain of FOXC2 transcriptional activity, as measured by transactivation assay using FOXC1/C2 response element reporter; a frameshift truncated mutant protein localizes to nuclear aggregates while all mutants retain nuclear localization.","method":"Luciferase reporter transactivation assay; subcellular localization by immunofluorescence; mutagenesis analysis","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — functional transcriptional assay with disease mutants and localization studies, single lab","pmids":["27276711"],"is_preprint":false},{"year":2017,"finding":"FOXC2 interacts with YAP and TEAD to activate YAP signaling, which in turn positively regulates Hexokinase 2 (HK2) expression and promotes glycolysis in nasopharyngeal carcinoma cells.","method":"Co-immunoprecipitation (FOXC2-YAP-TEAD complex); gene expression analysis; HK2 expression and glycolysis assays; in vitro and in vivo tumor assays","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 3 — Co-IP for complex identification, functional glycolysis assay, single lab","pmids":["28433696"],"is_preprint":false},{"year":2017,"finding":"TLR4 signaling in lung endothelial cells induces ERK phosphorylation, which causes ERK-FOXC2 protein interaction, ERK-dependent FOXC2 serine/threonine phosphorylation, and subsequent FOXC2 transcriptional activation of DLL4 (master regulator of sprouting angiogenesis); FOXC2 directly binds the DLL4 promoter in vivo; this TLR4-ERK-FOXC2-DLL4 axis regulates inflammatory angiogenesis.","method":"ERK-FOXC2 co-immunoprecipitation; FOXC2 phosphorylation assay; ChIP (FOXC2 binding to DLL4 promoter); FOXC2 siRNA and ERK dominant negative; in vivo LPS mouse model; retinal angiogenesis assay","journal":"The Journal of physiology","confidence":"High","confidence_rationale":"Tier 1-2 — direct ChIP of FOXC2 on DLL4 promoter, protein interaction by Co-IP, in vivo and in vitro corroboration with multiple orthogonal approaches","pmids":["29380370"],"is_preprint":false},{"year":2017,"finding":"Foxc2 coordinates white adipose tissue inflammation and browning through the leptin-JAK2/STAT3 pathway; STAT3 physically interacts with PRDM16 to form a complex that promotes WAT browning; CREB is required for Foxc2-mediated inflammation regulation; Foxc2-mediated suppression of JAK2/STAT3 and promotion of STAT3-PRDM16 complex were confirmed by ChIP and Co-IP.","method":"Co-immunoprecipitation (STAT3-PRDM16 complex); ChIP (CREB on leptin and Foxc2 promoters); LPS-induced inflammatory model; ob/ob mouse comparison; Foxc2 overexpression in HFD-obese mice","journal":"International journal of obesity (2005)","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP and ChIP used, single lab with multiple approaches but complex multi-pathway claims","pmids":["28925407"],"is_preprint":false},{"year":2019,"finding":"Crystal structures of the FOXC2 DNA-binding domain (DBD) in complex with two different DNA sites reveal the winged-helix fold mechanism: helix H3 makes all base-specific contacts, while the N-terminus, wing 1, and C-terminus of FOXC2-DBD make additional contacts with DNA phosphate groups; structural analysis provides molecular basis for disease-causing mutations.","method":"X-ray crystallography (two crystal structures); biochemical binding assays; bioinformatics analysis; mutagenesis of disease-causing mutations","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with biochemical and mutagenesis validation, mechanistic DNA recognition model revised","pmids":["30722065"],"is_preprint":false},{"year":2019,"finding":"H19 lncRNA directly binds Foxc2 protein (confirmed by RNA immunoprecipitation and RNA pulldown); H19 and Foxc2 synergistically promote osteogenic differentiation of BMSCs; Foxc2 directly binds the Wnt4 promoter (confirmed by ChIP) and promotes its transcription, activating the Wnt-beta-catenin pathway.","method":"RNA immunoprecipitation; RNA pulldown; ChIP (Foxc2 binding to Wnt4 promoter); osteogenic differentiation assays; qRT-PCR and Western blot","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — direct RNA-protein interaction and ChIP validated, but single lab","pmids":["30633332"],"is_preprint":false},{"year":2020,"finding":"FOXC2 exhibits cell cycle-dependent expression with protein levels accumulating in G2 and rapidly decreasing during mitosis; PLK1 kinase activity is required for FOXC2 protein stability; FOXC2 knockdown delays mitotic entry in CSC-enriched TNBC cells; FOXC2-expressing cells are sensitive to PLK1 inhibition.","method":"Cell cycle synchronization; FOXC2 protein level analysis through cell cycle; PLK1 inhibitor treatment; RNAi knockdown; mitotic entry assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2-3 — cell cycle and PLK1 dependency established, but PLK1-FOXC2 phosphosite not mapped, single lab","pmids":["27064522"],"is_preprint":false},{"year":2020,"finding":"FOXC2 shear stimulation specifically increases ROCK activation and disrupts cell junctions in lymphatic endothelial cells; FOXC2 deletion increases focal adherens and disrupts junctional integrity via ROCK; ROCK inhibition rescues junctional integrity changes induced by FOXC2 inactivation in vitro and ameliorates valve degeneration in Foxc2 mutant mice in vivo.","method":"Shear stress experiments on human LECs; FOXC2 knockdown; ROCK inhibition; inducible endothelial-specific Foxc2 knockout mice; postnatal valve analysis","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 — in vitro mechanotransduction assay with pharmacological rescue validated in conditional knockout mouse model","pmids":["32510325"],"is_preprint":false},{"year":2021,"finding":"Inactivation of mechanosensitive transcription factor Foxc2 in adult lymphatic endothelium compromises gut epithelial barrier, promotes dysbiosis and bacterial translocation, and skews lymphatic endothelial subtype specialization toward pro-fibrotic identities; commensal microbiota depletion corrected intestinal lymphatic dysfunction, revealing a cross-talk between lymphatic vascular function and commensal microbiota.","method":"Inducible adult-specific Foxc2 knockout mice; single-cell RNA sequencing; antibiotic microbiota depletion; intestinal lymphatic function assays; cytokine and metabolite profiling","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 — inducible conditional KO with single-cell atlas and mechanistic microbiota rescue experiment","pmids":["34272244"],"is_preprint":false},{"year":2022,"finding":"Exosomal circKIF18A from M2 microglia binds to FOXC2 protein, maintains its stability and promotes its nuclear translocation in brain endothelial cells; nuclear FOXC2 then directly binds the promoters of ITGB3, CXCR4, and DLL4 to upregulate their expression and activate PI3K/AKT signaling, promoting GBM angiogenesis.","method":"Co-culture with microglial exosomes; circKIF18A-FOXC2 interaction assay; FOXC2 nuclear translocation imaging; ChIP (FOXC2 binding to ITGB3, CXCR4, DLL4 promoters); in vitro angiogenesis assays; in vivo tumorigenicity","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2-3 — ChIP for direct FOXC2 promoter binding, exosome-protein interaction assay, but complex multi-step mechanism in single study","pmids":["35637250"],"is_preprint":false},{"year":2023,"finding":"FOXC1 and FOXC2 directly bind to regulatory elements of the CXCL12 (in blood endothelial cells) and RSPO3 (in lymphatic endothelial cells) loci, respectively; vascular EC- and LEC-specific deletion of Foxc genes impairs CXCL12 and RSPO3 expression, reducing Wnt signaling in intestinal stem cells and worsening ischemia-reperfusion-induced intestinal damage; exogenous CXCL12 and RSPO3 rescue intestinal damage in respective Foxc mutants.","method":"EC/LEC-specific conditional Foxc1/Foxc2 knockout mice; ChIP (FOXC1/2 binding to CXCL12 and RSPO3 loci); Wnt signaling analysis in ISCs; CXCL12/RSPO3 rescue experiments; I/R injury model","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 1-2 — direct ChIP-confirmed binding with conditional knockout, defined pathway, and rescue experiments","pmids":["37154714"],"is_preprint":false},{"year":2023,"finding":"FOXC2 drives vasculogenic mimicry (VM) in solid tumors by transcriptionally activating endothelial genes in tumor cells; hypoxia stimulates this activity; VM-proficient tumors resistant to anti-angiogenic therapy become sensitized when FOXC2 is suppressed.","method":"Loss-of-function in diverse solid tumor cell lines; gene expression profiling; in vitro VM assays; in vivo anti-angiogenic therapy combination experiments","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple tumor types tested, functional in vivo assay, but direct FOXC2 target genes mediating VM not fully mapped","pmids":["37499655"],"is_preprint":false}],"current_model":"FOXC2 is a forkhead/winged-helix transcription factor whose DNA-binding domain (helix H3 making base-specific contacts, with wing 1, N- and C-termini contacting phosphates) directly binds Forkhead response elements to activate or repress target genes (including DLL4, Itgb3, integrin beta1, Wnt4, CXCL12, RSPO3, p120-catenin, and mtTFA/Tfam); its transcriptional activity is regulated by multiple post-translational modifications—phosphorylation at eight proline-directed sites controls chromatin recruitment, CK2-mediated phosphorylation at S124 sequesters it in the cytoplasm of epithelial cells, p38-mediated phosphorylation at S367 controls its stability and pro-metastatic function, and Cdk5 phosphorylates it in lymphatic endothelium—while SUMOylation at synergy control motifs and de-SUMOylation by SENP3 reversibly inhibit or potentiate its activity; FOXC2 acts upstream of Notch/DLL4 signaling for arterial specification, regulates lymphatic valve morphogenesis through mechanotransduction and calcineurin/NFAT signaling in cooperation with PROX1 and connexin37, controls ERK signaling in lymphatic endothelial cell proliferation, modulates adipocyte metabolism by altering PKA holoenzyme composition and driving mitochondrial biogenesis via mtTFA/Tfam, and promotes EMT and metastasis by repressing epithelial genes and activating mesenchymal programs including ZEB1."},"narrative":{"teleology":[{"year":1997,"claim":"Establishing that FOXC2 (MFH-1) is a transcriptional activator essential for mesenchymal morphogenesis resolved its basic molecular function and demonstrated that its loss causes lethal aortic arch and skeletal defects in mice.","evidence":"Transactivation assays of mouse/human MFH-1 protein; targeted gene knockout in mice with phenotypic analysis","pmids":["9409679","9169153"],"confidence":"High","gaps":["Precise DNA target sequences were unknown","Mechanism of transactivation domain function uncharacterized","Redundancy with FOXC1 not yet tested"]},{"year":2000,"claim":"Identification of truncating FOXC2 mutations as the cause of lymphedema-distichiasis syndrome established FOXC2 haploinsufficiency as the genetic basis for a human lymphatic disorder, connecting FOXC2 transcriptional function to lymphatic vascular development.","evidence":"Mutation sequencing, genetic linkage, and FISH mapping in affected families","pmids":["11078474","11371511"],"confidence":"High","gaps":["Molecular targets of FOXC2 in lymphatic endothelium unknown","Whether different mutation positions produce variable phenotypes was unclear","Animal model of lymphedema-distichiasis not yet generated"]},{"year":2001,"claim":"Demonstrating that FOXC2 alters PKA holoenzyme composition in adipocytes and that Foxc1/Foxc2 act upstream of Notch/Delta signaling in cardiovascular and somite patterning placed FOXC2 at two major signaling nodes—metabolic regulation and vascular specification.","evidence":"Transgenic FOXC2 overexpression in adipocytes with PKA analysis; compound Foxc1;Foxc2 knockout mice with Notch pathway gene expression","pmids":["11551504","11562355"],"confidence":"High","gaps":["Direct FOXC2 transcriptional targets in adipocytes not identified","Whether FOXC2 directly binds Notch pathway gene promoters was untested","Lymphatic-specific roles of Foxc2 vs. Foxc1 not separated"]},{"year":2006,"claim":"Showing that Foxc2 directly activates the DLL4 promoter via a Foxc-binding element and that compound Foxc mutants lack arterial markers resolved how FOXC2 instructs arterial cell identity upstream of Notch signaling.","evidence":"Direct Dll4 promoter activation assay; compound knockout mice with arteriovenous malformation phenotype and gene expression","pmids":["16678147","16839542"],"confidence":"High","gaps":["Genome-wide set of direct FOXC2 targets in endothelium unknown","Post-translational regulation of FOXC2 in vascular cells not yet explored","How FOXC2 distinguishes arterial from venous programs mechanistically unclear"]},{"year":2007,"claim":"Discovery that EMT master regulators (Snail, Twist, Goosecoid) induce FOXC2, and that FOXC2 is required for lung metastasis, established FOXC2 as a critical effector of EMT and metastatic colonization beyond its developmental roles.","evidence":"RNAi knockdown and overexpression in mouse mammary carcinoma cells; in vivo lung metastasis assay","pmids":["17537911"],"confidence":"High","gaps":["Direct transcriptional targets mediating FOXC2-driven EMT not identified","How FOXC2 nuclear vs. cytoplasmic localization affects EMT unresolved","Post-translational modifications controlling FOXC2 in cancer context unknown"]},{"year":2008,"claim":"Identification of integrin β3 as a direct FOXC2 transcriptional target in endothelial cells, with functional validation by neutralizing antibody rescue, provided the first mechanistic link between FOXC2 and integrin-mediated angiogenesis.","evidence":"Promoter binding assay; ITGB3 antibody rescue of FOXC2-driven migration; Foxc2 heterozygous mice with impaired microvessel outgrowth","pmids":["18579532"],"confidence":"High","gaps":["Full repertoire of FOXC2-regulated integrins unknown","Signaling downstream of ITGB3 in FOXC2-driven angiogenesis not characterized"]},{"year":2009,"claim":"Showing that FOXC2 subcellular localization (cytoplasmic vs. nuclear) determines whether it promotes epithelial maintenance or mesenchymal transition revealed a binary switch model for FOXC2 function, and that FOXC2 directly represses p120-catenin explained how it destabilizes adherens junctions.","evidence":"RNAi and overexpression with subcellular fractionation in epithelial vs. fibroblast cells; EMSA confirming direct FOXC2 binding to p120-catenin promoter","pmids":["19935708","20460685"],"confidence":"High","gaps":["Kinase controlling cytoplasmic retention unknown","Full mechanism of p120-catenin repression (cofactors, chromatin remodeling) not explored"]},{"year":2012,"claim":"Discovery that FOXC2, PROX1, and shear stress cooperatively induce connexin37 and calcineurin/NFAT signaling for lymphatic valve formation, combined with demonstration that SUMOylation at synergy control motifs inhibits FOXC2 transcriptional activity, established the mechanotransduction pathway and a key post-translational regulatory mechanism.","evidence":"Shear stress assays in LECs with genetic mouse models; in vitro SUMOylation reconstitution with purified components and SENP2 reversal; mutagenesis","pmids":["22306086","22493429"],"confidence":"High","gaps":["Identity of the kinase(s) driving FOXC2 phosphorylation in shear response unknown","Whether SUMOylation regulates FOXC2 specifically in lymphatic cells untested","Structural basis for SUMOylation effects on DNA binding unclear"]},{"year":2013,"claim":"Genome-wide ChIP-seq mapping of FOXC2 in LECs combined with phosphosite mutagenesis showed that phosphorylation at eight proline-directed sites controls chromatin recruitment in a site-selective, rheostat-like manner, and SENP3-mediated de-SUMOylation was shown to potentiate FOXC2 transcriptional activity toward EMT targets like N-cadherin.","evidence":"ChIP-seq in LECs; mass spectrometry phosphosite mapping; phosphorylation-deficient mutants failing to remodel vasculature in vivo; SENP3 knockdown/overexpression with EMT readouts","pmids":["23878394","25216525"],"confidence":"High","gaps":["Identity of the proline-directed kinase(s) not determined","Interplay between phosphorylation and SUMOylation on same FOXC2 molecule unknown","Whether SENP3 regulation of FOXC2 operates in lymphatic endothelium not tested"]},{"year":2014,"claim":"Identification of CK2 as the kinase phosphorylating FOXC2 at S124 to enforce cytoplasmic retention in epithelial cells resolved the localization switch: loss of CK2β in breast cancer permits nuclear FOXC2 accumulation and mesenchymal gene activation.","evidence":"In vitro CK2 kinase assay; S124L/S124D mutagenesis with localization and migration phenotypes; CK2 knockdown/overexpression","pmids":["25486430"],"confidence":"High","gaps":["Whether CK2-FOXC2 axis operates in lymphatic endothelium unknown","Other kinases contributing to cytoplasmic retention not excluded","Crystal structure of phospho-S124 FOXC2 not determined"]},{"year":2015,"claim":"Mapping p38 phosphorylation of FOXC2 at S367 as essential for protein stability, EMT induction, and selective metastasis promotion (without affecting primary tumor growth), and identifying Cdk5 as a FOXC2 kinase in lymphatic endothelium, defined two context-specific phosphorylation events governing FOXC2 in cancer and lymphatic development.","evidence":"S367E/S367A mutagenesis with orthotopic syngeneic tumor model; Cdk5 substrate identification with endothelial-specific knockout and lymphatic valve phenotype","pmids":["27292262","26027726"],"confidence":"High","gaps":["Whether Cdk5 phosphorylates the same sites as proline-directed kinases unclear","How p38-FOXC2-ZEB1 axis interfaces with CK2-mediated S124 regulation unknown","Cdk5-specific phosphosites on FOXC2 not mapped"]},{"year":2017,"claim":"Demonstration that TLR4-ERK signaling phosphorylates FOXC2 to activate DLL4 transcription in inflammatory angiogenesis, and that FOXC2 interacts with YAP-TEAD to promote glycolysis, expanded FOXC2's role to innate immune–vascular coupling and metabolic reprogramming.","evidence":"ERK-FOXC2 Co-IP; ChIP of FOXC2 on DLL4 promoter in endothelial cells; LPS in vivo model; FOXC2-YAP-TEAD Co-IP with HK2 expression analysis","pmids":["29380370","28433696"],"confidence":"High","gaps":["ERK phosphosite(s) on FOXC2 not mapped","YAP-TEAD interaction validated only by Co-IP without reciprocal or structural confirmation","Whether ERK-FOXC2-DLL4 axis operates in lymphatic endothelium untested"]},{"year":2019,"claim":"Crystal structures of the FOXC2 DNA-binding domain revealed how helix H3 makes all base-specific contacts while wing 1 and terminal regions contact the phosphate backbone, providing a structural framework to interpret disease-causing mutations and FOXC2 target selection.","evidence":"X-ray crystallography of FOXC2-DBD bound to two DNA sequences; biochemical binding assays; disease mutation mapping","pmids":["30722065"],"confidence":"High","gaps":["Full-length FOXC2 structure with transactivation domain absent","Structural basis for cofactor interaction (e.g., PROX1, YAP) unknown","How post-translational modifications alter DNA-binding geometry not resolved"]},{"year":2020,"claim":"Establishing that FOXC2 controls lymphatic junctional integrity via ROCK signaling, with ROCK inhibition rescuing valve degeneration in Foxc2 mutant mice, identified a pharmacologically targetable effector downstream of FOXC2 in lymphedema pathogenesis.","evidence":"Shear stress in LECs; FOXC2 knockdown and ROCK inhibition; inducible endothelial-specific Foxc2 knockout mice with postnatal valve analysis","pmids":["32510325"],"confidence":"High","gaps":["Whether FOXC2 directly transcribes ROCK pathway genes or acts indirectly unknown","Long-term therapeutic efficacy of ROCK inhibition in lymphedema not assessed","FOXC2 cell cycle dependency (PLK1-mediated stability) not integrated with lymphatic function"]},{"year":2023,"claim":"ChIP-confirmed direct FOXC2 binding to CXCL12 and RSPO3 regulatory elements in vascular and lymphatic endothelium, with rescue experiments, established a paracrine mechanism by which endothelial FOXC2 sustains intestinal stem cell Wnt signaling and epithelial barrier integrity.","evidence":"EC/LEC-specific conditional Foxc knockout mice; ChIP; CXCL12/RSPO3 rescue in ischemia-reperfusion injury model","pmids":["37154714"],"confidence":"High","gaps":["Whether this paracrine mechanism operates in other organs unknown","FOXC2 vs. FOXC1 differential target gene specificity at these loci not resolved","Post-translational modifications controlling FOXC2 in intestinal endothelium unexplored"]},{"year":null,"claim":"Key unresolved questions include: which proline-directed kinase(s) phosphorylate the eight conserved sites controlling chromatin recruitment, how the multiple post-translational modifications (phosphorylation, SUMOylation) are integrated on individual FOXC2 molecules in different cell types, and whether the structural basis for cofactor interactions (PROX1, YAP-TEAD) can explain target gene selectivity.","evidence":"","pmids":[],"confidence":"Low","gaps":["Identity of proline-directed kinase(s) for the eight conserved sites","Full-length FOXC2 structure including transactivation domain","Integrated model of how multiple PTMs coordinate context-specific FOXC2 output"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,6,9,13,15,33,34,39]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,5,6,13,14,23,25,29,31,39]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[10,22,29,33,38]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[10,22]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,3,6,16,21,25,27,31]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,1,3,6,7,11,16,24,26]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,5,13,14,17,23,29,34,39]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[2,5,14,30,32]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[17,18,19,22,25,35]}],"complexes":[],"partners":["FOXC1","PROX1","SENP3","YAP1","CDK5","CSNK2A1","MAPK14","ERK2"],"other_free_text":[]},"mechanistic_narrative":"FOXC2 is a forkhead/winged-helix transcription factor that functions as a master regulator of vascular development, lymphatic valve morphogenesis, adipocyte metabolism, and epithelial-mesenchymal transition. Its DNA-binding domain uses helix H3 for base-specific contacts while wing 1 and terminal regions engage the phosphate backbone, enabling direct transcriptional activation of targets including DLL4, ITGB3, CXCL12, RSPO3, p120-catenin, Wnt4, and mtTFA/Tfam [PMID:30722065, PMID:16678147, PMID:37154714, PMID:21270254]. FOXC2 transcriptional output is tuned by multiple post-translational modifications: proline-directed phosphorylation at eight sites controls chromatin recruitment in a rheostat-like manner, CK2 phosphorylation at S124 sequesters FOXC2 in the cytoplasm, p38-mediated phosphorylation at S367 governs protein stability and EMT/metastasis via ZEB1, and SUMOylation at synergy control motifs inhibits activity while SENP3-mediated de-SUMOylation potentiates it [PMID:23878394, PMID:25486430, PMID:27292262, PMID:22493429, PMID:25216525]. Loss-of-function mutations in FOXC2 cause lymphedema-distichiasis syndrome through haploinsufficiency, reflecting its essential role in lymphatic development where it cooperates with PROX1 to transduce shear-stress signals through calcineurin/NFAT and connexin37 and restrains ERK-driven lymphatic endothelial proliferation [PMID:11078474, PMID:22306086, PMID:27214551]."},"prefetch_data":{"uniprot":{"accession":"Q99958","full_name":"Forkhead box protein C2","aliases":["Forkhead-related protein FKHL14","Mesenchyme fork head protein 1","MFH-1 protein","Transcription factor FKH-14"],"length_aa":501,"mass_kda":53.7,"function":"Transcriptional activator","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q99958/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FOXC2","classification":"Not Classified","n_dependent_lines":57,"n_total_lines":1208,"dependency_fraction":0.04718543046357616},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FOXC2","total_profiled":1310},"omim":[{"mim_id":"609218","title":"FOVEAL HYPOPLASIA 2; FVH2","url":"https://www.omim.org/entry/609218"},{"mim_id":"608748","title":"BONE MORPHOGENETIC PROTEIN 10; BMP10","url":"https://www.omim.org/entry/608748"},{"mim_id":"605597","title":"FORKHEAD TRANSCRIPTION FACTOR FOXL2; FOXL2","url":"https://www.omim.org/entry/605597"},{"mim_id":"605120","title":"GROWTH/DIFFERENTIATION FACTOR 2; GDF2","url":"https://www.omim.org/entry/605120"},{"mim_id":"603252","title":"FORKHEAD BOX L1; FOXL1","url":"https://www.omim.org/entry/603252"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nuclear bodies","reliability":"Supported"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"blood vessel","ntpm":37.0}],"url":"https://www.proteinatlas.org/search/FOXC2"},"hgnc":{"alias_symbol":["MFH-1"],"prev_symbol":["FKHL14"]},"alphafold":{"accession":"Q99958","domains":[{"cath_id":"1.10.10.10","chopping":"75-158","consensus_level":"high","plddt":93.6048,"start":75,"end":158}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99958","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99958-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99958-F1-predicted_aligned_error_v6.png","plddt_mean":55.16},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FOXC2","jax_strain_url":"https://www.jax.org/strain/search?query=FOXC2"},"sequence":{"accession":"Q99958","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99958.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99958/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99958"}},"corpus_meta":[{"pmid":"17537911","id":"PMC_17537911","title":"Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17537911","citation_count":486,"is_preprint":false},{"pmid":"11078474","id":"PMC_11078474","title":"Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome.","date":"2000","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11078474","citation_count":454,"is_preprint":false},{"pmid":"11551504","id":"PMC_11551504","title":"FOXC2 is a winged helix gene that counteracts obesity, hypertriglyceridemia, and diet-induced insulin resistance.","date":"2001","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/11551504","citation_count":439,"is_preprint":false},{"pmid":"22306086","id":"PMC_22306086","title":"Mechanotransduction, PROX1, and FOXC2 cooperate to control connexin37 and calcineurin during lymphatic-valve formation.","date":"2012","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/22306086","citation_count":333,"is_preprint":false},{"pmid":"11562355","id":"PMC_11562355","title":"The murine winged helix transcription factors, Foxc1 and Foxc2, are both required for cardiovascular development and somitogenesis.","date":"2001","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/11562355","citation_count":291,"is_preprint":false},{"pmid":"10704385","id":"PMC_10704385","title":"Murine forkhead/winged helix genes Foxc1 (Mf1) and Foxc2 (Mfh1) are required for the early organogenesis of the kidney and urinary tract.","date":"2000","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/10704385","citation_count":274,"is_preprint":false},{"pmid":"16678147","id":"PMC_16678147","title":"The forkhead transcription factors, Foxc1 and Foxc2, are required for arterial specification and lymphatic sprouting during vascular development.","date":"2006","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16678147","citation_count":224,"is_preprint":false},{"pmid":"9409679","id":"PMC_9409679","title":"Essential roles of the winged helix transcription factor MFH-1 in aortic arch patterning and skeletogenesis.","date":"1997","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/9409679","citation_count":207,"is_preprint":false},{"pmid":"28323030","id":"PMC_28323030","title":"Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/28323030","citation_count":171,"is_preprint":false},{"pmid":"11371511","id":"PMC_11371511","title":"Truncating mutations in FOXC2 cause multiple lymphedema syndromes.","date":"2001","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11371511","citation_count":171,"is_preprint":false},{"pmid":"17372167","id":"PMC_17372167","title":"Mutations in FOXC2 are strongly associated with primary valve failure in veins of the lower limb.","date":"2007","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/17372167","citation_count":146,"is_preprint":false},{"pmid":"16839542","id":"PMC_16839542","title":"Forkhead transcription factors, Foxc1 and Foxc2, are required for the morphogenesis of the cardiac outflow tract.","date":"2006","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16839542","citation_count":128,"is_preprint":false},{"pmid":"14569043","id":"PMC_14569043","title":"Reduced expression of FOXC2 and brown adipogenic genes in human subjects with insulin resistance.","date":"2003","source":"Obesity research","url":"https://pubmed.ncbi.nlm.nih.gov/14569043","citation_count":119,"is_preprint":false},{"pmid":"22410781","id":"PMC_22410781","title":"MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22410781","citation_count":109,"is_preprint":false},{"pmid":"11499682","id":"PMC_11499682","title":"Analysis of lymphoedema-distichiasis families for FOXC2 mutations reveals small insertions and deletions throughout the gene.","date":"2001","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11499682","citation_count":97,"is_preprint":false},{"pmid":"15196959","id":"PMC_15196959","title":"The forkhead genes, Foxc1 and Foxc2, regulate paraxial versus intermediate mesoderm cell fate.","date":"2004","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/15196959","citation_count":87,"is_preprint":false},{"pmid":"20059958","id":"PMC_20059958","title":"Pax3:Foxc2 reciprocal repression in the somite modulates muscular versus vascular cell fate choice in multipotent progenitors.","date":"2009","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/20059958","citation_count":87,"is_preprint":false},{"pmid":"8674414","id":"PMC_8674414","title":"Clustered arrangement of winged helix genes fkh-6 and MFH-1: possible implications for mesoderm development.","date":"1996","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/8674414","citation_count":84,"is_preprint":false},{"pmid":"20043076","id":"PMC_20043076","title":"Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFbeta, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors.","date":"2010","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20043076","citation_count":80,"is_preprint":false},{"pmid":"15465483","id":"PMC_15465483","title":"Foxc2 is expressed in developing lymphatic vessels and other tissues associated with lymphedema-distichiasis syndrome.","date":"2004","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/15465483","citation_count":79,"is_preprint":false},{"pmid":"26210254","id":"PMC_26210254","title":"FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer.","date":"2015","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/26210254","citation_count":76,"is_preprint":false},{"pmid":"35392966","id":"PMC_35392966","title":"Stanniocalcin 1 promotes metastasis, lipid metabolism and cisplatin chemoresistance via the FOXC2/ITGB6 signaling axis in ovarian cancer.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/35392966","citation_count":75,"is_preprint":false},{"pmid":"18579532","id":"PMC_18579532","title":"The Foxc2 transcription factor regulates angiogenesis via induction of integrin beta3 expression.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18579532","citation_count":73,"is_preprint":false},{"pmid":"26804168","id":"PMC_26804168","title":"Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26804168","citation_count":73,"is_preprint":false},{"pmid":"34272244","id":"PMC_34272244","title":"FOXC2 controls adult lymphatic endothelial specialization, function, and gut lymphatic barrier preventing multiorgan failure.","date":"2021","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/34272244","citation_count":70,"is_preprint":false},{"pmid":"19935708","id":"PMC_19935708","title":"Mesenchymal-epithelial transition in epithelial response to injury: the role of Foxc2.","date":"2009","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/19935708","citation_count":68,"is_preprint":false},{"pmid":"27214551","id":"PMC_27214551","title":"Foxc1 and Foxc2 deletion causes abnormal lymphangiogenesis and correlates with ERK hyperactivation.","date":"2016","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27214551","citation_count":65,"is_preprint":false},{"pmid":"15277530","id":"PMC_15277530","title":"The forkhead transcription factor FoxC2 inhibits white adipocyte differentiation.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15277530","citation_count":65,"is_preprint":false},{"pmid":"25069037","id":"PMC_25069037","title":"FOXC2 promotes colorectal cancer proliferation through inhibition of FOXO3a and activation of MAPK and AKT signaling pathways.","date":"2014","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/25069037","citation_count":59,"is_preprint":false},{"pmid":"20429416","id":"PMC_20429416","title":"The cooperative roles of Foxc1 and Foxc2 in cardiovascular development.","date":"2009","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/20429416","citation_count":55,"is_preprint":false},{"pmid":"25216525","id":"PMC_25216525","title":"De-SUMOylation of FOXC2 by SENP3 promotes the epithelial-mesenchymal transition in gastric cancer cells.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25216525","citation_count":55,"is_preprint":false},{"pmid":"31882321","id":"PMC_31882321","title":"Coactivation of Endogenous Wnt10b and Foxc2 by CRISPR Activation Enhances BMSC Osteogenesis and Promotes Calvarial Bone Regeneration.","date":"2019","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31882321","citation_count":54,"is_preprint":false},{"pmid":"29216867","id":"PMC_29216867","title":"Protein kinase C α enhances migration of breast cancer cells through FOXC2-mediated repression of p120-catenin.","date":"2017","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29216867","citation_count":53,"is_preprint":false},{"pmid":"27292262","id":"PMC_27292262","title":"Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27292262","citation_count":53,"is_preprint":false},{"pmid":"21270254","id":"PMC_21270254","title":"The adipocyte-expressed forkhead transcription factor Foxc2 regulates metabolism through altered mitochondrial function.","date":"2011","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/21270254","citation_count":52,"is_preprint":false},{"pmid":"33505426","id":"PMC_33505426","title":"YTHDF2 Inhibits Gastric Cancer Cell Growth by Regulating FOXC2 Signaling Pathway.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33505426","citation_count":51,"is_preprint":false},{"pmid":"32249539","id":"PMC_32249539","title":"Circular RNA PVT1 promotes metastasis via regulating of miR-526b/FOXC2 signals in OS cells.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32249539","citation_count":51,"is_preprint":false},{"pmid":"29341903","id":"PMC_29341903","title":"Emerging roles and mechanisms of FOXC2 in cancer.","date":"2018","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29341903","citation_count":50,"is_preprint":false},{"pmid":"32510325","id":"PMC_32510325","title":"Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/32510325","citation_count":50,"is_preprint":false},{"pmid":"20425831","id":"PMC_20425831","title":"Haploinsufficiencies of FOXF1 and FOXC2 genes associated with lethal alveolar capillary dysplasia and congenital heart disease.","date":"2010","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/20425831","citation_count":50,"is_preprint":false},{"pmid":"23502673","id":"PMC_23502673","title":"Dietary obesity-induced Egr-1 in adipocytes facilitates energy storage via suppression of FOXC2.","date":"2013","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/23502673","citation_count":49,"is_preprint":false},{"pmid":"30633332","id":"PMC_30633332","title":"H19 and Foxc2 synergistically promotes osteogenic differentiation of BMSCs via Wnt-β-catenin pathway.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30633332","citation_count":48,"is_preprint":false},{"pmid":"30722065","id":"PMC_30722065","title":"Structural basis for DNA recognition by FOXC2.","date":"2019","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/30722065","citation_count":45,"is_preprint":false},{"pmid":"20460685","id":"PMC_20460685","title":"p120-catenin is transcriptionally downregulated by FOXC2 in non-small cell lung cancer cells.","date":"2010","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/20460685","citation_count":44,"is_preprint":false},{"pmid":"26113535","id":"PMC_26113535","title":"Foxc2 enhances proliferation and inhibits apoptosis through activating Akt/mTORC1 signaling pathway in mouse preadipocytes.","date":"2015","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/26113535","citation_count":42,"is_preprint":false},{"pmid":"28253399","id":"PMC_28253399","title":"Foxc1 and Foxc2 in the Neural Crest Are Required for Ocular Anterior Segment Development.","date":"2017","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/28253399","citation_count":42,"is_preprint":false},{"pmid":"26027726","id":"PMC_26027726","title":"Cdk5 controls lymphatic vessel development and function by phosphorylation of Foxc2.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26027726","citation_count":42,"is_preprint":false},{"pmid":"32513911","id":"PMC_32513911","title":"LncRNA FOXC2-AS1 enhances FOXC2 mRNA stability to promote colorectal cancer progression via activation of Ca2+-FAK signal pathway.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32513911","citation_count":41,"is_preprint":false},{"pmid":"28433696","id":"PMC_28433696","title":"FOXC2 positively regulates YAP signaling and promotes the glycolysis of nasopharyngeal carcinoma.","date":"2017","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/28433696","citation_count":41,"is_preprint":false},{"pmid":"35637250","id":"PMC_35637250","title":"Glioblastoma-associated microglia-derived exosomal circKIF18A promotes angiogenesis by targeting FOXC2.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35637250","citation_count":40,"is_preprint":false},{"pmid":"28925407","id":"PMC_28925407","title":"Foxc2 coordinates inflammation and browning of white adipose by leptin-STAT3-PRDM16 signal in mice.","date":"2017","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/28925407","citation_count":40,"is_preprint":false},{"pmid":"26079578","id":"PMC_26079578","title":"Combining Foxc2 and Connexin37 deletions in mice leads to severe defects in lymphatic vascular growth and remodeling.","date":"2015","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/26079578","citation_count":40,"is_preprint":false},{"pmid":"23614500","id":"PMC_23614500","title":"The clinical significance of mesenchyme forkhead 1 (FoxC2) in gastric carcinoma.","date":"2013","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/23614500","citation_count":40,"is_preprint":false},{"pmid":"21640215","id":"PMC_21640215","title":"The forkhead transcription factor Foxc2 promotes osteoblastogenesis via up-regulation of integrin β1 expression.","date":"2011","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/21640215","citation_count":39,"is_preprint":false},{"pmid":"34324140","id":"PMC_34324140","title":"FOXC2-AS1 stabilizes FOXC2 mRNA via association with NSUN2 in gastric cancer cells.","date":"2021","source":"Human cell","url":"https://pubmed.ncbi.nlm.nih.gov/34324140","citation_count":38,"is_preprint":false},{"pmid":"15906099","id":"PMC_15906099","title":"Lymphoedema-distichiasis and FOXC2: unreported mutations, de novo mutation estimate, families without coding mutations.","date":"2005","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15906099","citation_count":38,"is_preprint":false},{"pmid":"20431116","id":"PMC_20431116","title":"Notch signaling, wt1 and foxc2 are key regulators of the podocyte gene regulatory network in Xenopus.","date":"2010","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20431116","citation_count":37,"is_preprint":false},{"pmid":"25587036","id":"PMC_25587036","title":"Notch1 acts via Foxc2 to promote definitive hematopoiesis via effects on hemogenic endothelium.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25587036","citation_count":37,"is_preprint":false},{"pmid":"23300339","id":"PMC_23300339","title":"BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation.","date":"2013","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/23300339","citation_count":37,"is_preprint":false},{"pmid":"19760751","id":"PMC_19760751","title":"Novel missense mutations in the FOXC2 gene alter transcriptional activity.","date":"2009","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/19760751","citation_count":36,"is_preprint":false},{"pmid":"37499655","id":"PMC_37499655","title":"FOXC2 promotes vasculogenic mimicry and resistance to anti-angiogenic therapy.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37499655","citation_count":35,"is_preprint":false},{"pmid":"24122419","id":"PMC_24122419","title":"Foxc2 over-expression in bone marrow mesenchymal stem cells stimulates osteogenic differentiation and inhibits adipogenic differentiation.","date":"2014","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24122419","citation_count":35,"is_preprint":false},{"pmid":"22522965","id":"PMC_22522965","title":"Generation of conditional alleles for Foxc1 and Foxc2 in mice.","date":"2012","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/22522965","citation_count":35,"is_preprint":false},{"pmid":"32341351","id":"PMC_32341351","title":"Decreased ZNF750 promotes angiogenesis in a paracrine manner via activating DANCR/miR-4707-3p/FOXC2 axis in esophageal squamous cell carcinoma.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32341351","citation_count":34,"is_preprint":false},{"pmid":"30389560","id":"PMC_30389560","title":"Long noncoding RNA FOXC2-AS1 facilitates the proliferation and progression of prostate cancer via targeting miR-1253/EZH2.","date":"2018","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/30389560","citation_count":33,"is_preprint":false},{"pmid":"19540201","id":"PMC_19540201","title":"The forkhead transcription factor Foxc2 stimulates osteoblast differentiation.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19540201","citation_count":33,"is_preprint":false},{"pmid":"23878394","id":"PMC_23878394","title":"Phosphorylation regulates FOXC2-mediated transcription in lymphatic endothelial cells.","date":"2013","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23878394","citation_count":33,"is_preprint":false},{"pmid":"21464574","id":"PMC_21464574","title":"Mutations in FOXC2 in humans (lymphoedema distichiasis syndrome) cause lymphatic dysfunction on dependency.","date":"2011","source":"Journal of vascular research","url":"https://pubmed.ncbi.nlm.nih.gov/21464574","citation_count":33,"is_preprint":false},{"pmid":"22374725","id":"PMC_22374725","title":"Nuclear localization of GLI1 and elevated expression of FOXC2 in breast cancer is associated with the basal-like phenotype.","date":"2012","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/22374725","citation_count":32,"is_preprint":false},{"pmid":"22174714","id":"PMC_22174714","title":"The Role of FoxC2 Transcription Factor in Tumor Angiogenesis.","date":"2011","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22174714","citation_count":32,"is_preprint":false},{"pmid":"12383817","id":"PMC_12383817","title":"Lymphedema-distichiasis syndrome and FOXC2 gene mutation.","date":"2002","source":"American journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/12383817","citation_count":32,"is_preprint":false},{"pmid":"12485195","id":"PMC_12485195","title":"FOXC2 truncating mutation in distichiasis, lymphedema, and cleft palate.","date":"2002","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12485195","citation_count":31,"is_preprint":false},{"pmid":"26808710","id":"PMC_26808710","title":"Arterialization and anomalous vein wall remodeling in varicose veins is associated with upregulated FoxC2-Dll4 pathway.","date":"2016","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26808710","citation_count":30,"is_preprint":false},{"pmid":"28724617","id":"PMC_28724617","title":"Human venous valve disease caused by mutations in FOXC2 and GJC2.","date":"2017","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28724617","citation_count":30,"is_preprint":false},{"pmid":"23815774","id":"PMC_23815774","title":"Foxc2 regulates osteogenesis and angiogenesis of bone marrow mesenchymal stem cells.","date":"2013","source":"BMC musculoskeletal disorders","url":"https://pubmed.ncbi.nlm.nih.gov/23815774","citation_count":30,"is_preprint":false},{"pmid":"27336949","id":"PMC_27336949","title":"Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.","date":"2016","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27336949","citation_count":30,"is_preprint":false},{"pmid":"24700112","id":"PMC_24700112","title":"Overexpressed FOXC2 in ovarian cancer enhances the epithelial-to-mesenchymal transition and invasion of ovarian cancer cells.","date":"2014","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24700112","citation_count":30,"is_preprint":false},{"pmid":"29380370","id":"PMC_29380370","title":"Endothelial immune activation programmes cell-fate decisions and angiogenesis by inducing angiogenesis regulator DLL4 through TLR4-ERK-FOXC2 signalling.","date":"2018","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29380370","citation_count":29,"is_preprint":false},{"pmid":"19394045","id":"PMC_19394045","title":"Sporadic in utero generalized edema caused by mutations in the lymphangiogenic genes VEGFR3 and FOXC2.","date":"2009","source":"The Journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/19394045","citation_count":29,"is_preprint":false},{"pmid":"25822012","id":"PMC_25822012","title":"Downregulation of FoxC2 Increased Susceptibility to Experimental Colitis: Influence of Lymphatic Drainage Function?","date":"2015","source":"Inflammatory bowel diseases","url":"https://pubmed.ncbi.nlm.nih.gov/25822012","citation_count":28,"is_preprint":false},{"pmid":"18197197","id":"PMC_18197197","title":"Primary non-syndromic lymphoedema (Meige disease) is not caused by mutations in FOXC2.","date":"2008","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/18197197","citation_count":28,"is_preprint":false},{"pmid":"22493429","id":"PMC_22493429","title":"Small ubiquitin-like modifier (SUMO) modification mediates function of the inhibitory domains of developmental regulators FOXC1 and FOXC2.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22493429","citation_count":28,"is_preprint":false},{"pmid":"31379747","id":"PMC_31379747","title":"Insulin Enhances Migration and Invasion in Prostate Cancer Cells by Up-Regulation of FOXC2.","date":"2019","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31379747","citation_count":27,"is_preprint":false},{"pmid":"30302523","id":"PMC_30302523","title":"FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.","date":"2018","source":"Cancer chemotherapy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30302523","citation_count":26,"is_preprint":false},{"pmid":"27276711","id":"PMC_27276711","title":"FOXC2 disease-mutations identified in lymphedema-distichiasis patients cause both loss and gain of protein function.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27276711","citation_count":26,"is_preprint":false},{"pmid":"27819350","id":"PMC_27819350","title":"α-MSH and Foxc2 promote fatty acid oxidation through C/EBPβ negative transcription in mice adipose tissue.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27819350","citation_count":26,"is_preprint":false},{"pmid":"24278289","id":"PMC_24278289","title":"FOXC2 mutations in familial and sporadic spinal extradural arachnoid cyst.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24278289","citation_count":26,"is_preprint":false},{"pmid":"9169153","id":"PMC_9169153","title":"Isolation of the mouse (MFH-1) and human (FKHL 14) mesenchyme fork head-1 genes reveals conservation of their gene and protein structures.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9169153","citation_count":26,"is_preprint":false},{"pmid":"25486430","id":"PMC_25486430","title":"Casein kinase 2 prevents mesenchymal transformation by maintaining Foxc2 in the cytoplasm.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25486430","citation_count":25,"is_preprint":false},{"pmid":"32271448","id":"PMC_32271448","title":"LncRNA FOXC2-AS1 regulated proliferation and apoptosis of vascular smooth muscle cell through targeting miR-1253/FOXF1 axis in atherosclerosis.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32271448","citation_count":25,"is_preprint":false},{"pmid":"37154714","id":"PMC_37154714","title":"Endothelial FOXC1 and FOXC2 promote intestinal regeneration after ischemia-reperfusion injury.","date":"2023","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/37154714","citation_count":23,"is_preprint":false},{"pmid":"27064522","id":"PMC_27064522","title":"FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27064522","citation_count":23,"is_preprint":false},{"pmid":"27904711","id":"PMC_27904711","title":"Naringin promotes osteogenic differentiation of bone marrow stromal cells by up-regulating Foxc2 expression via the IHH signaling pathway.","date":"2016","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/27904711","citation_count":23,"is_preprint":false},{"pmid":"22098677","id":"PMC_22098677","title":"Adipocyte mitochondrial genes and the forkhead factor FOXC2 are decreased in type 2 diabetes patients and normalized in response to rosiglitazone.","date":"2011","source":"Diabetology & metabolic syndrome","url":"https://pubmed.ncbi.nlm.nih.gov/22098677","citation_count":23,"is_preprint":false},{"pmid":"26893778","id":"PMC_26893778","title":"Downregulation of Foxc2 enhances apoptosis induced by 5-fluorouracil through activation of MAPK and AKT pathways in colorectal cancer.","date":"2016","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/26893778","citation_count":23,"is_preprint":false},{"pmid":"14566319","id":"PMC_14566319","title":"Mutation of the FOXC2 gene in familial distichiasis.","date":"2003","source":"Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus","url":"https://pubmed.ncbi.nlm.nih.gov/14566319","citation_count":22,"is_preprint":false},{"pmid":"30376688","id":"PMC_30376688","title":"Foxc2 is required for proper cardiac neural crest cell migration, outflow tract septation, and ventricle expansion.","date":"2018","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/30376688","citation_count":22,"is_preprint":false},{"pmid":"15597109","id":"PMC_15597109","title":"Role of the FOXC2 -512C>T polymorphism in type 2 diabetes: possible association with the dysmetabolic syndrome.","date":"2005","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/15597109","citation_count":22,"is_preprint":false},{"pmid":"10722840","id":"PMC_10722840","title":"MFH-1 is required for bone morphogenetic protein-2-induced osteoblastic differentiation of C2C12 myoblasts.","date":"2000","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10722840","citation_count":20,"is_preprint":false},{"pmid":"28223138","id":"PMC_28223138","title":"Foxc1 and Foxc2 are necessary to maintain glomerular podocytes.","date":"2017","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/28223138","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48443,"output_tokens":9993,"usd":0.147612},"stage2":{"model":"claude-opus-4-6","input_tokens":13869,"output_tokens":4541,"usd":0.274305},"total_usd":0.421917,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"FOXC2 (MFH-1) protein acts as a positive transcriptional transactivator, as demonstrated by transcriptional activity assays of the mouse and human MFH-1 proteins, and is essential for aortic arch patterning and skeletogenesis in vivo as shown by targeted gene knockout in mice.\",\n      \"method\": \"Transcriptional activity assay; targeted gene knockout in mice with phenotypic analysis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro transactivation assay plus knockout model with defined phenotypic readout, replicated across two papers (PMID:9409679, PMID:9169153)\",\n      \"pmids\": [\"9409679\", \"9169153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Loss-of-function mutations (nonsense and frameshift) in FOXC2, a forkhead/winged-helix transcription factor, cause lymphedema-distichiasis syndrome via FOXC2 haploinsufficiency, establishing FOXC2 as required for lymphatic development.\",\n      \"method\": \"Mutation identification by sequencing; genetic linkage; FISH mapping\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (sequencing, linkage, FISH), replicated extensively across subsequent studies\",\n      \"pmids\": [\"11078474\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"FOXC2 overexpression in adipocytes increases sensitivity of the beta-adrenergic-cAMP-PKA signaling pathway by altering adipocyte PKA holoenzyme composition, leading to a lean, insulin-sensitive phenotype and counteracting obesity and hypertriglyceridemia.\",\n      \"method\": \"Transgenic mouse overexpression; gene expression profiling; PKA holoenzyme composition analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mechanistic pathway placement with in vivo gain-of-function and biochemical PKA assay, single high-impact study with multiple orthogonal methods\",\n      \"pmids\": [\"11551504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Foxc1 and Foxc2 have dose-dependent, cooperative roles in cardiovascular development and somitogenesis; compound Foxc1;Foxc2 homozygous knockout mice show complete absence of segmented paraxial mesoderm and profound defects in branchial arches and blood vessel remodeling, with loss of Notch pathway target gene expression (Mesp1, Mesp2, Hes5, Notch1, Dll1, Lfng, ephrinB2), placing Foxc1/2 upstream of the Notch/Delta/Mesp regulatory loop.\",\n      \"method\": \"Compound knockout mouse genetics; gene expression analysis; epistasis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with compound knockouts and multiple molecular readouts, replicated in subsequent cardiovascular studies\",\n      \"pmids\": [\"11562355\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Truncating mutations throughout FOXC2 that disrupt the DNA-binding domain and/or C-terminal alpha-helices essential for transcription activation cause multiple lymphedema syndromes, demonstrating these domains are functionally required.\",\n      \"method\": \"Mutation sequencing in 86 lymphedema families; domain-function correlation\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — large patient cohort with domain mapping, but functional assay not directly performed in this study\",\n      \"pmids\": [\"11371511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"FoxC2 inhibits white adipocyte differentiation (adipogenesis) by blocking the ability of PPARgamma to promote expression of a subset of adipogenic genes (C/EBPalpha, adiponectin, perilipin) without affecting PPARgamma DNA binding or transactivation from a PPARgamma response element directly.\",\n      \"method\": \"Overexpression in 3T3-L1 preadipocytes and Swiss fibroblasts; PPARgamma overexpression rescue experiments; reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal cell-based assays with defined molecular pathway placement and PPARgamma rescue experiments\",\n      \"pmids\": [\"15277530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Foxc1 and Foxc2 directly activate the Dll4 promoter via a Foxc-binding site to induce arterial cell specification upstream of Notch signaling; compound Foxc1;Foxc2 mutant embryos lack arterial markers and display arteriovenous malformations and defects in lymphatic sprouting due to reduced VEGF-C.\",\n      \"method\": \"Compound knockout mouse genetics; in vitro overexpression; direct promoter activation assay (Dll4 promoter with Foxc-binding site); gene expression analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct promoter binding and activation combined with in vivo knockout epistasis, replicated across multiple vascular studies\",\n      \"pmids\": [\"16678147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Foxc1 and Foxc2 are required for cardiac outflow tract morphogenesis; compound mutants show downregulation of Tbx1 and Fgf8/10 in the second heart field and extensive neural crest cell apoptosis during migration, placing Foxc genes upstream of the Tbx1-FGF cascade.\",\n      \"method\": \"Compound knockout mouse genetics; gene expression analysis; cell proliferation and apoptosis assays\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with defined molecular cascade identification\",\n      \"pmids\": [\"16839542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"FOXC2 expression is induced by EMT-inducing signals (TGF-beta1, Snail, Twist, Goosecoid) and is required for the mesenchymal component of EMT; knockdown impairs lung metastasis of mammary carcinoma cells, and overexpression enhances metastatic ability in mouse models.\",\n      \"method\": \"Loss-of-function (RNAi) and gain-of-function (overexpression) in mouse mammary carcinoma cells; in vivo lung metastasis assay; gene expression profiling\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain/loss-of-function with in vivo readout, multiple EMT inducers tested, highly cited foundational study\",\n      \"pmids\": [\"17537911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Foxc2 directly regulates angiogenesis by binding to multiple Forkhead-binding elements within the Itgb3 (integrin beta3) promoter to drive Itgb3 expression; Foxc2 overexpression enhances endothelial cell migration and adhesion, an effect blocked by Itgb3 neutralizing antibody; Foxc2 heterozygous mutant mice show reduced Itgb3 expression and impaired microvessel outgrowth.\",\n      \"method\": \"Gene expression profiling; promoter binding assay; Itgb3 neutralizing antibody rescue; aortic ring ex vivo sprouting assay; Foxc2 heterozygous mouse model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct promoter binding demonstrated, functional rescue with neutralizing antibody, corroborated with in vivo mouse model\",\n      \"pmids\": [\"18579532\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FOXC2 subcellular localization determines its function: cytoplasmic FOXC2 in normal epithelial cells promotes epithelial redifferentiation, while nuclear FOXC2 promotes mesenchymal/EMT phenotype; silencing FOXC2 in epithelial cells causes EMT and increased migration, whereas in fibroblasts it causes increased epithelial marker expression; overexpression in renal epithelial cells drives de novo nuclear localization and mesenchymal phenotype.\",\n      \"method\": \"RNAi knockdown; overexpression; subcellular fractionation/immunofluorescence; kidney ischemia-reperfusion in vivo model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — localization-function linkage established by RNAi and overexpression with defined phenotypic readouts, single lab\",\n      \"pmids\": [\"19935708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Pax3 and Foxc2 exhibit reciprocal transcriptional repression in the somite dermomyotome, and the Pax3:Foxc2 ratio determines myogenic versus vascular smooth muscle cell fate in multipotent progenitors.\",\n      \"method\": \"Genetic approaches (compound mouse mutants); somite explant manipulation; epistasis analysis\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with multiple approaches and defined cell fate readouts\",\n      \"pmids\": [\"20059958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Foxc2 stimulates osteoblast differentiation by activating canonical Wnt-beta-catenin/TCF-LEF signaling, and this effect is partially mediated by protein kinase A (PKA), as the PKA inhibitor H-89 suppresses Foxc2-mediated TCF/LEF transcriptional activity.\",\n      \"method\": \"Electroporation overexpression in cranial suture mesenchymal cells; siRNA knockdown; reporter (TCF/LEF luciferase) assay; pharmacological inhibition (H-89)\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple methods but single lab, pathway placement via reporter assay and inhibitor\",\n      \"pmids\": [\"19540201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Foxc2 directly binds to the p120-catenin promoter between positions +267 and +282 (confirmed by EMSA) and transcriptionally represses p120-catenin expression in NSCLC cells; FOXC2 silencing restores p120-catenin and subsequently E-cadherin levels.\",\n      \"method\": \"Serial deletion promoter analysis; EMSA (electromobility shift assay); RNAi silencing; reporter assay\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct DNA binding confirmed by EMSA plus functional RNAi rescue, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"20460685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FOXC2 expression in adipocytes induces mitochondriogenesis, elongated mitochondrial morphology, increased aerobic metabolic capacity, and specifically trans-activates the nuclear-encoded mitochondrial transcription factor A (mtTFA/Tfam) gene promoter—a function unique among tested forkhead genes.\",\n      \"method\": \"Quantitative RT-PCR; promoter assay (trans-activation); electron microscopy; oxygen consumption and palmitate oxidation measurements\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct promoter trans-activation combined with multiple functional metabolic readouts\",\n      \"pmids\": [\"21270254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Foxc2 promotes osteoblastogenesis by directly binding to a Forkhead-binding element in the integrin beta1 promoter and up-regulating integrin beta1 expression, with downstream activation of Akt and ERK phosphorylation.\",\n      \"method\": \"Promoter binding assay (direct binding to Forkhead element); siRNA knockdown; overexpression in MC3T3-E1 and primary calvarial cells; ex vivo organ culture\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter binding demonstrated, functional cell assays, single lab\",\n      \"pmids\": [\"21640215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PROX1, FOXC2, and flow (shear stress) coordinately control expression of connexin37 (gap junction protein) and activation of calcineurin/NFAT signaling to mediate lymphatic valve formation; FOXC2 mediates mechanosensory responses to shear stress in lymphatic endothelial cells.\",\n      \"method\": \"In vitro shear stress experiments; genetic mouse models; gene expression analysis; functional valve morphogenesis assays\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro mechanotransduction assay combined with in vivo genetic models and multiple molecular readouts\",\n      \"pmids\": [\"22306086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SUMOylation of FOXC2 occurs primarily at one consensus synergy control motif (with minor contribution of a second site) and negatively regulates FOXC2 transcriptional activity; SUMOylation can be reconstituted in vitro with purified components and reversed by SUMO protease SENP2; SUMOylation-deficient FOXC2 mutants show higher transcriptional activity.\",\n      \"method\": \"In vitro SUMOylation reconstitution with purified components; SENP2 protease reversal; mutagenesis of synergy control motifs; transcriptional activity assay; detection of endogenous SUMO2/3-modified FOXC1\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro with purified components plus mutagenesis and functional assays\",\n      \"pmids\": [\"22493429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FOXC2 is phosphorylated on eight evolutionarily conserved proline-directed serine/threonine residues; phosphorylation regulates FOXC2 chromatin recruitment in a site-selective (rheostat-like) manner in lymphatic endothelial cells; phosphorylation-deficient FOXC2 mutant fails to induce vascular remodeling in vivo.\",\n      \"method\": \"Genome-wide ChIP-seq in lymphatic endothelial cells; phosphorylation-deficient mutagenesis; in vivo vascular remodeling assay; mass spectrometry\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genome-wide location analysis combined with mutagenesis and in vivo functional validation\",\n      \"pmids\": [\"23878394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SENP3 de-SUMOylates FOXC2, potentiating its transcriptional activity; de-SUMOylated FOXC2 transcriptionally activates N-cadherin expression, promoting EMT in gastric cancer; reactive oxygen species-induced de-SUMOylation of FOXC2 is blocked by silencing SENP3.\",\n      \"method\": \"Biochemical SUMO assay; SENP3 overexpression/knockdown; target gene expression analysis; nude mouse model\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical identification of FOXC2 as SENP3 substrate with functional consequence on transcription and EMT, multiple approaches\",\n      \"pmids\": [\"25216525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Egr-1 in adipocytes suppresses FOXC2 expression, thereby promoting energy storage in white adipose tissue; Egr-1 null mice show elevated FOXC2 expression and its target genes, leading to increased energy expenditure and protection from diet-induced obesity.\",\n      \"method\": \"Egr-1 null mouse model; gene expression analysis in WAT; correlation of Egr-1 and FOXC2 expression\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — knockout mouse with defined FOXC2 pathway placement, but direct Egr-1 binding to FOXC2 promoter not demonstrated in this study\",\n      \"pmids\": [\"23502673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BSTA promotes mTORC2-mediated phosphorylation of Akt1 at Ser473, which suppresses FOXC2 expression to stimulate adipocyte differentiation; the mTORC2-BSTA-Akt1-FoxC2 signaling axis is required for adipogenesis.\",\n      \"method\": \"BSTA gene-trap murine ES cells; co-immunoprecipitation (BSTA-Akt1 complex); phosphorylation assays; FOXC2 expression analysis\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP demonstrating complex, genetic loss-of-function, and defined signaling cascade with pathway placement\",\n      \"pmids\": [\"23300339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Casein kinase 2 (CK2) associates with Foxc2 and phosphorylates it at serine 124 in vitro; CK2-mediated phosphorylation at S124 maintains Foxc2 in the cytoplasm of normal epithelial cells; mutation of S124 to leucine causes constitutive nuclear Foxc2 localization and mesenchymal gene expression, while S124D phosphomimetic causes constitutive cytoplasmic localization; loss of CK2beta in breast cancer correlates with nuclear FOXC2.\",\n      \"method\": \"In vitro kinase assay (CK2 phosphorylation of Foxc2); mutagenesis (S124L, S124D); subcellular localization imaging; CK2 knockdown/overexpression; cell migration assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay plus mutagenesis of phosphosite with functional localization and phenotypic readouts\",\n      \"pmids\": [\"25486430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FOXC2 acts as a transcriptional repressor of p120-catenin (CTNND1) downstream of PKCalpha, leading to destabilization of E-cadherin at adherens junctions; ChIP confirmed direct FOXC2 binding to the p120-catenin promoter; inhibition of PKCalpha or FOXC2 rescues p120-catenin and E-cadherin, reducing tumor cell migration.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP); luciferase promoter reporter assay; Western blot; transwell migration/invasion assays; RNAi\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP confirmed direct DNA binding, promoter reporter assay, functional cell migration rescue\",\n      \"pmids\": [\"29216867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Cyclin-dependent kinase 5 (Cdk5) phosphorylates Foxc2 in lymphatic endothelial cells; Cdk5 is an essential regulator of lymphatic vessel development and valve formation, mechanistically linked through Foxc2 as its key substrate.\",\n      \"method\": \"Endothelial-specific Cdk5 knockdown; identification of Foxc2 as Cdk5 substrate; lymphatic vessel and valve phenotype analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — substrate identification with in vivo endothelial-specific knockdown and mechanistic pathway linkage\",\n      \"pmids\": [\"26027726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"p38 kinase phosphorylates FOXC2 at serine 367 (S367) to regulate its protein stability and function; the phosphomimetic FOXC2(S367E) mutant is refractory to p38 inhibition while FOXC2(S367A) non-phosphorylatable mutant fails to elicit EMT or upregulate ZEB1; p38-FOXC2 signaling selectively promotes metastasis without affecting primary tumor growth; ZEB1 is a downstream transcriptional target of FOXC2.\",\n      \"method\": \"Site-directed mutagenesis (S367E, S367A); orthotopic syngeneic mouse tumor model; p38 inhibitor (SB203580) treatment; gene expression analysis; in vitro EMT assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — phosphosite mutagenesis with in vivo and in vitro validation, multiple orthogonal methods\",\n      \"pmids\": [\"27292262\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Notch signaling acts upstream of Foxc2 in hemogenic endothelial cells to promote definitive hematopoiesis; Foxc2 is required for proper development of definitive hematopoiesis downstream of Notch, as shown in zebrafish, mouse embryos, and mouse ES cell differentiation assays.\",\n      \"method\": \"Mouse ES cell differentiation; zebrafish loss-of-function; mouse embryo Foxc2 analysis; epistasis with Notch induction\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in multiple model systems establishing pathway position\",\n      \"pmids\": [\"25587036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FOXC1 and FOXC2 regulate ERK signaling in lymphatic endothelial cells; LEC-specific deletion of Foxc1 or Foxc2 causes increased LEC proliferation and enlarged, abnormal lymphatic vessels associated with ERK hyperactivation; pharmacological ERK inhibition rescues the enlarged lymphatic vessel phenotype in FOXC-deficient embryos.\",\n      \"method\": \"LEC-specific conditional knockout mice; ERK signaling analysis; pharmacological ERK inhibition in utero; gene expression of Ras regulators\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional knockout with defined pathway identification and pharmacological rescue, replicated with multiple genetic combinations\",\n      \"pmids\": [\"27214551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"p38MAPK signaling is a druggable upstream regulator of FOXC2, and FOXC2 elevated by p38 promotes an AR-negative stem-like prostate cancer phenotype resistant to androgen deprivation therapy; p38 inhibition restores epithelial attributes and reduces circulating tumor cells in vivo.\",\n      \"method\": \"p38 inhibitor (SB203580) treatment; FOXC2 expression analysis; in vivo tumor model with circulating tumor cell analysis; RNAi\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — defined signaling axis with in vivo validation, but phosphosite not mapped in this study\",\n      \"pmids\": [\"26804168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FOXC2 disease mutations outside the forkhead domain cause either loss or gain of FOXC2 transcriptional activity, as measured by transactivation assay using FOXC1/C2 response element reporter; a frameshift truncated mutant protein localizes to nuclear aggregates while all mutants retain nuclear localization.\",\n      \"method\": \"Luciferase reporter transactivation assay; subcellular localization by immunofluorescence; mutagenesis analysis\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional transcriptional assay with disease mutants and localization studies, single lab\",\n      \"pmids\": [\"27276711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FOXC2 interacts with YAP and TEAD to activate YAP signaling, which in turn positively regulates Hexokinase 2 (HK2) expression and promotes glycolysis in nasopharyngeal carcinoma cells.\",\n      \"method\": \"Co-immunoprecipitation (FOXC2-YAP-TEAD complex); gene expression analysis; HK2 expression and glycolysis assays; in vitro and in vivo tumor assays\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP for complex identification, functional glycolysis assay, single lab\",\n      \"pmids\": [\"28433696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TLR4 signaling in lung endothelial cells induces ERK phosphorylation, which causes ERK-FOXC2 protein interaction, ERK-dependent FOXC2 serine/threonine phosphorylation, and subsequent FOXC2 transcriptional activation of DLL4 (master regulator of sprouting angiogenesis); FOXC2 directly binds the DLL4 promoter in vivo; this TLR4-ERK-FOXC2-DLL4 axis regulates inflammatory angiogenesis.\",\n      \"method\": \"ERK-FOXC2 co-immunoprecipitation; FOXC2 phosphorylation assay; ChIP (FOXC2 binding to DLL4 promoter); FOXC2 siRNA and ERK dominant negative; in vivo LPS mouse model; retinal angiogenesis assay\",\n      \"journal\": \"The Journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct ChIP of FOXC2 on DLL4 promoter, protein interaction by Co-IP, in vivo and in vitro corroboration with multiple orthogonal approaches\",\n      \"pmids\": [\"29380370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Foxc2 coordinates white adipose tissue inflammation and browning through the leptin-JAK2/STAT3 pathway; STAT3 physically interacts with PRDM16 to form a complex that promotes WAT browning; CREB is required for Foxc2-mediated inflammation regulation; Foxc2-mediated suppression of JAK2/STAT3 and promotion of STAT3-PRDM16 complex were confirmed by ChIP and Co-IP.\",\n      \"method\": \"Co-immunoprecipitation (STAT3-PRDM16 complex); ChIP (CREB on leptin and Foxc2 promoters); LPS-induced inflammatory model; ob/ob mouse comparison; Foxc2 overexpression in HFD-obese mice\",\n      \"journal\": \"International journal of obesity (2005)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP and ChIP used, single lab with multiple approaches but complex multi-pathway claims\",\n      \"pmids\": [\"28925407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structures of the FOXC2 DNA-binding domain (DBD) in complex with two different DNA sites reveal the winged-helix fold mechanism: helix H3 makes all base-specific contacts, while the N-terminus, wing 1, and C-terminus of FOXC2-DBD make additional contacts with DNA phosphate groups; structural analysis provides molecular basis for disease-causing mutations.\",\n      \"method\": \"X-ray crystallography (two crystal structures); biochemical binding assays; bioinformatics analysis; mutagenesis of disease-causing mutations\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with biochemical and mutagenesis validation, mechanistic DNA recognition model revised\",\n      \"pmids\": [\"30722065\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"H19 lncRNA directly binds Foxc2 protein (confirmed by RNA immunoprecipitation and RNA pulldown); H19 and Foxc2 synergistically promote osteogenic differentiation of BMSCs; Foxc2 directly binds the Wnt4 promoter (confirmed by ChIP) and promotes its transcription, activating the Wnt-beta-catenin pathway.\",\n      \"method\": \"RNA immunoprecipitation; RNA pulldown; ChIP (Foxc2 binding to Wnt4 promoter); osteogenic differentiation assays; qRT-PCR and Western blot\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct RNA-protein interaction and ChIP validated, but single lab\",\n      \"pmids\": [\"30633332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FOXC2 exhibits cell cycle-dependent expression with protein levels accumulating in G2 and rapidly decreasing during mitosis; PLK1 kinase activity is required for FOXC2 protein stability; FOXC2 knockdown delays mitotic entry in CSC-enriched TNBC cells; FOXC2-expressing cells are sensitive to PLK1 inhibition.\",\n      \"method\": \"Cell cycle synchronization; FOXC2 protein level analysis through cell cycle; PLK1 inhibitor treatment; RNAi knockdown; mitotic entry assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — cell cycle and PLK1 dependency established, but PLK1-FOXC2 phosphosite not mapped, single lab\",\n      \"pmids\": [\"27064522\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FOXC2 shear stimulation specifically increases ROCK activation and disrupts cell junctions in lymphatic endothelial cells; FOXC2 deletion increases focal adherens and disrupts junctional integrity via ROCK; ROCK inhibition rescues junctional integrity changes induced by FOXC2 inactivation in vitro and ameliorates valve degeneration in Foxc2 mutant mice in vivo.\",\n      \"method\": \"Shear stress experiments on human LECs; FOXC2 knockdown; ROCK inhibition; inducible endothelial-specific Foxc2 knockout mice; postnatal valve analysis\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro mechanotransduction assay with pharmacological rescue validated in conditional knockout mouse model\",\n      \"pmids\": [\"32510325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Inactivation of mechanosensitive transcription factor Foxc2 in adult lymphatic endothelium compromises gut epithelial barrier, promotes dysbiosis and bacterial translocation, and skews lymphatic endothelial subtype specialization toward pro-fibrotic identities; commensal microbiota depletion corrected intestinal lymphatic dysfunction, revealing a cross-talk between lymphatic vascular function and commensal microbiota.\",\n      \"method\": \"Inducible adult-specific Foxc2 knockout mice; single-cell RNA sequencing; antibiotic microbiota depletion; intestinal lymphatic function assays; cytokine and metabolite profiling\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — inducible conditional KO with single-cell atlas and mechanistic microbiota rescue experiment\",\n      \"pmids\": [\"34272244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Exosomal circKIF18A from M2 microglia binds to FOXC2 protein, maintains its stability and promotes its nuclear translocation in brain endothelial cells; nuclear FOXC2 then directly binds the promoters of ITGB3, CXCR4, and DLL4 to upregulate their expression and activate PI3K/AKT signaling, promoting GBM angiogenesis.\",\n      \"method\": \"Co-culture with microglial exosomes; circKIF18A-FOXC2 interaction assay; FOXC2 nuclear translocation imaging; ChIP (FOXC2 binding to ITGB3, CXCR4, DLL4 promoters); in vitro angiogenesis assays; in vivo tumorigenicity\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — ChIP for direct FOXC2 promoter binding, exosome-protein interaction assay, but complex multi-step mechanism in single study\",\n      \"pmids\": [\"35637250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FOXC1 and FOXC2 directly bind to regulatory elements of the CXCL12 (in blood endothelial cells) and RSPO3 (in lymphatic endothelial cells) loci, respectively; vascular EC- and LEC-specific deletion of Foxc genes impairs CXCL12 and RSPO3 expression, reducing Wnt signaling in intestinal stem cells and worsening ischemia-reperfusion-induced intestinal damage; exogenous CXCL12 and RSPO3 rescue intestinal damage in respective Foxc mutants.\",\n      \"method\": \"EC/LEC-specific conditional Foxc1/Foxc2 knockout mice; ChIP (FOXC1/2 binding to CXCL12 and RSPO3 loci); Wnt signaling analysis in ISCs; CXCL12/RSPO3 rescue experiments; I/R injury model\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct ChIP-confirmed binding with conditional knockout, defined pathway, and rescue experiments\",\n      \"pmids\": [\"37154714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FOXC2 drives vasculogenic mimicry (VM) in solid tumors by transcriptionally activating endothelial genes in tumor cells; hypoxia stimulates this activity; VM-proficient tumors resistant to anti-angiogenic therapy become sensitized when FOXC2 is suppressed.\",\n      \"method\": \"Loss-of-function in diverse solid tumor cell lines; gene expression profiling; in vitro VM assays; in vivo anti-angiogenic therapy combination experiments\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple tumor types tested, functional in vivo assay, but direct FOXC2 target genes mediating VM not fully mapped\",\n      \"pmids\": [\"37499655\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FOXC2 is a forkhead/winged-helix transcription factor whose DNA-binding domain (helix H3 making base-specific contacts, with wing 1, N- and C-termini contacting phosphates) directly binds Forkhead response elements to activate or repress target genes (including DLL4, Itgb3, integrin beta1, Wnt4, CXCL12, RSPO3, p120-catenin, and mtTFA/Tfam); its transcriptional activity is regulated by multiple post-translational modifications—phosphorylation at eight proline-directed sites controls chromatin recruitment, CK2-mediated phosphorylation at S124 sequesters it in the cytoplasm of epithelial cells, p38-mediated phosphorylation at S367 controls its stability and pro-metastatic function, and Cdk5 phosphorylates it in lymphatic endothelium—while SUMOylation at synergy control motifs and de-SUMOylation by SENP3 reversibly inhibit or potentiate its activity; FOXC2 acts upstream of Notch/DLL4 signaling for arterial specification, regulates lymphatic valve morphogenesis through mechanotransduction and calcineurin/NFAT signaling in cooperation with PROX1 and connexin37, controls ERK signaling in lymphatic endothelial cell proliferation, modulates adipocyte metabolism by altering PKA holoenzyme composition and driving mitochondrial biogenesis via mtTFA/Tfam, and promotes EMT and metastasis by repressing epithelial genes and activating mesenchymal programs including ZEB1.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"FOXC2 is a forkhead/winged-helix transcription factor that functions as a master regulator of vascular development, lymphatic valve morphogenesis, adipocyte metabolism, and epithelial-mesenchymal transition. Its DNA-binding domain uses helix H3 for base-specific contacts while wing 1 and terminal regions engage the phosphate backbone, enabling direct transcriptional activation of targets including DLL4, ITGB3, CXCL12, RSPO3, p120-catenin, Wnt4, and mtTFA/Tfam [PMID:30722065, PMID:16678147, PMID:37154714, PMID:21270254]. FOXC2 transcriptional output is tuned by multiple post-translational modifications: proline-directed phosphorylation at eight sites controls chromatin recruitment in a rheostat-like manner, CK2 phosphorylation at S124 sequesters FOXC2 in the cytoplasm, p38-mediated phosphorylation at S367 governs protein stability and EMT/metastasis via ZEB1, and SUMOylation at synergy control motifs inhibits activity while SENP3-mediated de-SUMOylation potentiates it [PMID:23878394, PMID:25486430, PMID:27292262, PMID:22493429, PMID:25216525]. Loss-of-function mutations in FOXC2 cause lymphedema-distichiasis syndrome through haploinsufficiency, reflecting its essential role in lymphatic development where it cooperates with PROX1 to transduce shear-stress signals through calcineurin/NFAT and connexin37 and restrains ERK-driven lymphatic endothelial proliferation [PMID:11078474, PMID:22306086, PMID:27214551].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing that FOXC2 (MFH-1) is a transcriptional activator essential for mesenchymal morphogenesis resolved its basic molecular function and demonstrated that its loss causes lethal aortic arch and skeletal defects in mice.\",\n      \"evidence\": \"Transactivation assays of mouse/human MFH-1 protein; targeted gene knockout in mice with phenotypic analysis\",\n      \"pmids\": [\"9409679\", \"9169153\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise DNA target sequences were unknown\", \"Mechanism of transactivation domain function uncharacterized\", \"Redundancy with FOXC1 not yet tested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of truncating FOXC2 mutations as the cause of lymphedema-distichiasis syndrome established FOXC2 haploinsufficiency as the genetic basis for a human lymphatic disorder, connecting FOXC2 transcriptional function to lymphatic vascular development.\",\n      \"evidence\": \"Mutation sequencing, genetic linkage, and FISH mapping in affected families\",\n      \"pmids\": [\"11078474\", \"11371511\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular targets of FOXC2 in lymphatic endothelium unknown\", \"Whether different mutation positions produce variable phenotypes was unclear\", \"Animal model of lymphedema-distichiasis not yet generated\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrating that FOXC2 alters PKA holoenzyme composition in adipocytes and that Foxc1/Foxc2 act upstream of Notch/Delta signaling in cardiovascular and somite patterning placed FOXC2 at two major signaling nodes—metabolic regulation and vascular specification.\",\n      \"evidence\": \"Transgenic FOXC2 overexpression in adipocytes with PKA analysis; compound Foxc1;Foxc2 knockout mice with Notch pathway gene expression\",\n      \"pmids\": [\"11551504\", \"11562355\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct FOXC2 transcriptional targets in adipocytes not identified\", \"Whether FOXC2 directly binds Notch pathway gene promoters was untested\", \"Lymphatic-specific roles of Foxc2 vs. Foxc1 not separated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showing that Foxc2 directly activates the DLL4 promoter via a Foxc-binding element and that compound Foxc mutants lack arterial markers resolved how FOXC2 instructs arterial cell identity upstream of Notch signaling.\",\n      \"evidence\": \"Direct Dll4 promoter activation assay; compound knockout mice with arteriovenous malformation phenotype and gene expression\",\n      \"pmids\": [\"16678147\", \"16839542\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide set of direct FOXC2 targets in endothelium unknown\", \"Post-translational regulation of FOXC2 in vascular cells not yet explored\", \"How FOXC2 distinguishes arterial from venous programs mechanistically unclear\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Discovery that EMT master regulators (Snail, Twist, Goosecoid) induce FOXC2, and that FOXC2 is required for lung metastasis, established FOXC2 as a critical effector of EMT and metastatic colonization beyond its developmental roles.\",\n      \"evidence\": \"RNAi knockdown and overexpression in mouse mammary carcinoma cells; in vivo lung metastasis assay\",\n      \"pmids\": [\"17537911\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets mediating FOXC2-driven EMT not identified\", \"How FOXC2 nuclear vs. cytoplasmic localization affects EMT unresolved\", \"Post-translational modifications controlling FOXC2 in cancer context unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of integrin β3 as a direct FOXC2 transcriptional target in endothelial cells, with functional validation by neutralizing antibody rescue, provided the first mechanistic link between FOXC2 and integrin-mediated angiogenesis.\",\n      \"evidence\": \"Promoter binding assay; ITGB3 antibody rescue of FOXC2-driven migration; Foxc2 heterozygous mice with impaired microvessel outgrowth\",\n      \"pmids\": [\"18579532\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full repertoire of FOXC2-regulated integrins unknown\", \"Signaling downstream of ITGB3 in FOXC2-driven angiogenesis not characterized\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showing that FOXC2 subcellular localization (cytoplasmic vs. nuclear) determines whether it promotes epithelial maintenance or mesenchymal transition revealed a binary switch model for FOXC2 function, and that FOXC2 directly represses p120-catenin explained how it destabilizes adherens junctions.\",\n      \"evidence\": \"RNAi and overexpression with subcellular fractionation in epithelial vs. fibroblast cells; EMSA confirming direct FOXC2 binding to p120-catenin promoter\",\n      \"pmids\": [\"19935708\", \"20460685\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase controlling cytoplasmic retention unknown\", \"Full mechanism of p120-catenin repression (cofactors, chromatin remodeling) not explored\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Discovery that FOXC2, PROX1, and shear stress cooperatively induce connexin37 and calcineurin/NFAT signaling for lymphatic valve formation, combined with demonstration that SUMOylation at synergy control motifs inhibits FOXC2 transcriptional activity, established the mechanotransduction pathway and a key post-translational regulatory mechanism.\",\n      \"evidence\": \"Shear stress assays in LECs with genetic mouse models; in vitro SUMOylation reconstitution with purified components and SENP2 reversal; mutagenesis\",\n      \"pmids\": [\"22306086\", \"22493429\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the kinase(s) driving FOXC2 phosphorylation in shear response unknown\", \"Whether SUMOylation regulates FOXC2 specifically in lymphatic cells untested\", \"Structural basis for SUMOylation effects on DNA binding unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Genome-wide ChIP-seq mapping of FOXC2 in LECs combined with phosphosite mutagenesis showed that phosphorylation at eight proline-directed sites controls chromatin recruitment in a site-selective, rheostat-like manner, and SENP3-mediated de-SUMOylation was shown to potentiate FOXC2 transcriptional activity toward EMT targets like N-cadherin.\",\n      \"evidence\": \"ChIP-seq in LECs; mass spectrometry phosphosite mapping; phosphorylation-deficient mutants failing to remodel vasculature in vivo; SENP3 knockdown/overexpression with EMT readouts\",\n      \"pmids\": [\"23878394\", \"25216525\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the proline-directed kinase(s) not determined\", \"Interplay between phosphorylation and SUMOylation on same FOXC2 molecule unknown\", \"Whether SENP3 regulation of FOXC2 operates in lymphatic endothelium not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of CK2 as the kinase phosphorylating FOXC2 at S124 to enforce cytoplasmic retention in epithelial cells resolved the localization switch: loss of CK2β in breast cancer permits nuclear FOXC2 accumulation and mesenchymal gene activation.\",\n      \"evidence\": \"In vitro CK2 kinase assay; S124L/S124D mutagenesis with localization and migration phenotypes; CK2 knockdown/overexpression\",\n      \"pmids\": [\"25486430\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CK2-FOXC2 axis operates in lymphatic endothelium unknown\", \"Other kinases contributing to cytoplasmic retention not excluded\", \"Crystal structure of phospho-S124 FOXC2 not determined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Mapping p38 phosphorylation of FOXC2 at S367 as essential for protein stability, EMT induction, and selective metastasis promotion (without affecting primary tumor growth), and identifying Cdk5 as a FOXC2 kinase in lymphatic endothelium, defined two context-specific phosphorylation events governing FOXC2 in cancer and lymphatic development.\",\n      \"evidence\": \"S367E/S367A mutagenesis with orthotopic syngeneic tumor model; Cdk5 substrate identification with endothelial-specific knockout and lymphatic valve phenotype\",\n      \"pmids\": [\"27292262\", \"26027726\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Cdk5 phosphorylates the same sites as proline-directed kinases unclear\", \"How p38-FOXC2-ZEB1 axis interfaces with CK2-mediated S124 regulation unknown\", \"Cdk5-specific phosphosites on FOXC2 not mapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstration that TLR4-ERK signaling phosphorylates FOXC2 to activate DLL4 transcription in inflammatory angiogenesis, and that FOXC2 interacts with YAP-TEAD to promote glycolysis, expanded FOXC2's role to innate immune–vascular coupling and metabolic reprogramming.\",\n      \"evidence\": \"ERK-FOXC2 Co-IP; ChIP of FOXC2 on DLL4 promoter in endothelial cells; LPS in vivo model; FOXC2-YAP-TEAD Co-IP with HK2 expression analysis\",\n      \"pmids\": [\"29380370\", \"28433696\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ERK phosphosite(s) on FOXC2 not mapped\", \"YAP-TEAD interaction validated only by Co-IP without reciprocal or structural confirmation\", \"Whether ERK-FOXC2-DLL4 axis operates in lymphatic endothelium untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Crystal structures of the FOXC2 DNA-binding domain revealed how helix H3 makes all base-specific contacts while wing 1 and terminal regions contact the phosphate backbone, providing a structural framework to interpret disease-causing mutations and FOXC2 target selection.\",\n      \"evidence\": \"X-ray crystallography of FOXC2-DBD bound to two DNA sequences; biochemical binding assays; disease mutation mapping\",\n      \"pmids\": [\"30722065\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length FOXC2 structure with transactivation domain absent\", \"Structural basis for cofactor interaction (e.g., PROX1, YAP) unknown\", \"How post-translational modifications alter DNA-binding geometry not resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Establishing that FOXC2 controls lymphatic junctional integrity via ROCK signaling, with ROCK inhibition rescuing valve degeneration in Foxc2 mutant mice, identified a pharmacologically targetable effector downstream of FOXC2 in lymphedema pathogenesis.\",\n      \"evidence\": \"Shear stress in LECs; FOXC2 knockdown and ROCK inhibition; inducible endothelial-specific Foxc2 knockout mice with postnatal valve analysis\",\n      \"pmids\": [\"32510325\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FOXC2 directly transcribes ROCK pathway genes or acts indirectly unknown\", \"Long-term therapeutic efficacy of ROCK inhibition in lymphedema not assessed\", \"FOXC2 cell cycle dependency (PLK1-mediated stability) not integrated with lymphatic function\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"ChIP-confirmed direct FOXC2 binding to CXCL12 and RSPO3 regulatory elements in vascular and lymphatic endothelium, with rescue experiments, established a paracrine mechanism by which endothelial FOXC2 sustains intestinal stem cell Wnt signaling and epithelial barrier integrity.\",\n      \"evidence\": \"EC/LEC-specific conditional Foxc knockout mice; ChIP; CXCL12/RSPO3 rescue in ischemia-reperfusion injury model\",\n      \"pmids\": [\"37154714\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this paracrine mechanism operates in other organs unknown\", \"FOXC2 vs. FOXC1 differential target gene specificity at these loci not resolved\", \"Post-translational modifications controlling FOXC2 in intestinal endothelium unexplored\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: which proline-directed kinase(s) phosphorylate the eight conserved sites controlling chromatin recruitment, how the multiple post-translational modifications (phosphorylation, SUMOylation) are integrated on individual FOXC2 molecules in different cell types, and whether the structural basis for cofactor interactions (PROX1, YAP-TEAD) can explain target gene selectivity.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Identity of proline-directed kinase(s) for the eight conserved sites\", \"Full-length FOXC2 structure including transactivation domain\", \"Integrated model of how multiple PTMs coordinate context-specific FOXC2 output\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 6, 9, 13, 15, 33, 34, 39]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 5, 6, 13, 14, 23, 25, 29, 31, 39]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [10, 22, 29, 33, 38]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [10, 22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 3, 6, 16, 21, 25, 27, 31]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 1, 3, 6, 7, 11, 16, 24, 26]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 5, 13, 14, 17, 23, 29, 34, 39]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [2, 5, 14, 30, 32]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [17, 18, 19, 22, 25, 35]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"FOXC1\",\n      \"PROX1\",\n      \"SENP3\",\n      \"YAP1\",\n      \"CDK5\",\n      \"CSNK2A1\",\n      \"MAPK14\",\n      \"ERK2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}